Username


Password
Forgot Password?

Preview

Jesús San Miguel

Research Profile

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Anatomy

Register to see full profile

Co-author Network

Register to see all co-authors

Publications

  • TOP 3
  • Fermin M Sánchez-Guijo; Olga López-Villar; Lucía López-Anglada; Eva M Villarón; Sandra Muntión; María Díez-Campelo; Jose A Perez-Simón; Jesús F San Miguel; Dolores Caballero; Maria-Consuelo Del Cañizo
    Allogeneic mesenchymal stem cell therapy for refractory cytopenias after hematopoietic stem cell transplantation.
  • Asher A Chanan-Khan; Jesús F San Miguel; Sundar Jagannath; Heinz Ludwig; Meletios A Dimopoulos
    Novel therapeutic agents for the management of patients with multiple myeloma and renal impairment.
  • S Muntión; F M Sánchez-Guijo; S Carrancio; E Villarón; O López; M Diez-Campelo; J F San Miguel; M C del Cañizo
    Optimisation of mesenchymal stromal cells karyotyping analysis: implications for clinical use.
Register to see all publications

Register for free to view:

Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the research activity
of experts around the globe
Register to see more

Geonetwork of Jesús San Miguel (preview)

  • Cities where this author has publications
  • Cities where co-authors of this author have publications

Flash Player Required

Register to see more

All Publications

  • 2012: Fermin M Sánchez-Guijo; Olga López-Villar; Lucía López-Anglada; Eva M Villarón; Sandra Muntión; María Díez-Campelo; Jose A Perez-Simón; Jesús F San Miguel; Dolores Caballero; Maria-Consuelo Del Cañizo
    Allogeneic mesenchymal stem cell therapy for refractory cytopenias after hematopoietic stem cell transplantation.
    Transfusion 2012;52(5):1086-91.
  • 2012: Asher A Chanan-Khan; Jesús F San Miguel; Sundar Jagannath; Heinz Ludwig; Meletios A Dimopoulos
    Novel therapeutic agents for the management of patients with multiple myeloma and renal impairment.
    Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(8):2145-63.
  • 2012: S Muntión; F M Sánchez-Guijo; S Carrancio; E Villarón; O López; M Diez-Campelo; J F San Miguel; M C del Cañizo
    Optimisation of mesenchymal stromal cells karyotyping analysis: implications for clinical use.
    Transfusion medicine (Oxford, England) 2012;22(2):122-7.
  • 2012: Bruno Paiva; Norma C Gutiérrez; Laura Rosiñol; María-Belén Vídriales; María-Ángeles Montalbán; Joaquín Martínez-López; María-Victoria Mateos; María-Teresa Cibeira; Lourdes Cordón; Albert Oriol; et al.
    High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma.
    Blood 2012;119(3):687-91.
  • 2012: Antonio Garcia-Gomez; Enrique M Ocio; Edvan Crusoe; Carlos Santamaria; Pilar Hernández-Campo; Juan F Blanco; Fermin M Sanchez-Guijo; Teresa Hernández-Iglesias; Jesús G Briñón; Rosa M Fisac-Herrero; et al.
    Dasatinib as a bone-modifying agent: anabolic and anti-resorptive effects.
    PloS one 2012;7(4):e34914.
  • 2011: María-Victoria Mateos; Norma C Gutiérrez; María-Luisa Martín-Ramos; Bruno Paiva; María-Angeles Montalbán; Albert Oriol; Joaquín Martínez-López; Ana-Isabel Teruel; Enrique Bengoechea; Alejandro Martín; et al.
    Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance.
    Blood 2011;118(17):4547-53.
  • 2011: M Alcoceba; L Marín; A Balanzategui; M E Sarasquete; M C Chillón; P Martín-Jiménez; N Puig; C Santamaría; R Corral; R García-Sanz; et al.
    Frequency of HLA-A, -B and -DRB1 specificities and haplotypic associations in the population of Castilla y León (northwest-central Spain).
    Tissue antigens 2011;78(4):249-55.
  • 2011: Jesús F San-Miguel; María-Victoria Mateos
    Can multiple myeloma become a curable disease?
    Haematologica 2011;96(9):1246-8.
  • 2011: Antonio Palumbo; Maria-Victoria Mateos; Sara Bringhen; Jesús F San Miguel
    Practical management of adverse events in multiple myeloma: can therapy be attenuated in older patients?
    Blood reviews 2011;25(4):181-91.
  • 2011: Niels W C J van de Donk; Henk M Lokhorst; Meletios Dimopoulos; Michele Cavo; Gareth Morgan; Hermann Einsele; Martin Kropff; Steve Schey; Hervé Avet-Loiseau; Heinz Ludwig; et al.
    Treatment of relapsed and refractory multiple myeloma in the era of novel agents.
    Cancer treatment reviews 2011;37(4):266-83.
  • 2011: Michel Delforge; Evangelos Terpos; Paul G Richardson; Ofer Shpilberg; Nuriet K Khuageva; Rudolf Schlag; Meletios A Dimopoulos; Martin Kropff; Ivan Spicka; Maria T Petrucci; et al.
    Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma.
    European journal of haematology 2011;86(5):372-84.
  • 2011: Enrique Colado; Teresa Paíno; Patricia Maiso; Enrique M Ocio; Xi Chen; Stela Alvarez-Fernández; Norma C Gutiérrez; Jesús Martín-Sánchez; Juan Flores-Montero; Laura San Segundo; et al.
    Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response.
    Haematologica 2011;96(5):687-95.
  • 2011: Lucía López-Corral; Norma C Gutiérrez; Maria Belén Vidriales; Maria Victoria Mateos; Ana Rasillo; Ramón García-Sanz; Bruno Paiva; Jesús F San Miguel
    The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells.
    Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(7):1692-700.
  • 2011: B Paiva; M Pérez-Andrés; M-B Vídriales; J Almeida; N de las Heras; M-V Mateos; L López-Corral; N C Gutiérrez; J Blanco; A Oriol; et al.
    Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma.
    Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2011;25(4):697-706.
  • 2011: Bruno Paiva; María-Belén Vídriales; José J Pérez; María-Consuelo López-Berges; Ramón García-Sanz; Enrique M Ocio; Natalia de Las Heras; Rebeca Cuello; Alfonso García de Coca; Emilia Pardal; et al.
    The clinical utility and prognostic value of multiparameter flow cytometry immunophenotyping in light-chain amyloidosis.
    Blood 2011;117(13):3613-6.
  • 2011: María E Sarasquete; Norma C Gutiérrez; Irena Misiewicz-Krzeminska; Bruno Paiva; María C Chillón; Miguel Alcoceba; Ramón García-Sanz; Jesús M Hernández; Marcos González; Jesús F San-Miguel
    Upregulation of Dicer is more frequent in monoclonal gammopathies of undetermined significance than in multiple myeloma patients and is associated with longer survival in symptomatic myeloma patients.
    Haematologica 2011;96(3):468-71.
  • 2011: R García-Sanz; Em Ocio; A Caballero; R J P Magalhães; J Alonso; L López-Anglada; T Villaescusa; N Puig; J M Hernández; J Fernández-Calvo; et al.
    Post-treatment bone marrow residual disease > 5% by flow cytometry is highly predictive of short progression-free and overall survival in patients with Waldenström's macroglobulinemia.
    Clinical lymphoma, myeloma & leukemia 2011;11(1):168-71.
  • 2011: Joan Bladé; Pieter Sonneveld; Jesús F San Miguel; Heather J Sutherland; Roman Hajek; Arnon Nagler; Andrew Spencer; Tadeusz Robak; Keith C Lantz; Sen H Zhuang; et al.
    Efficacy and safety of pegylated liposomal Doxorubicin in combination with bortezomib for multiple myeloma: effects of adverse prognostic factors on outcome.
    Clinical lymphoma, myeloma & leukemia 2011;11(1):44-9.
  • 2011: Jesús F San-Miguel; Meletios A Dimopoulos; Edward A Stadtmauer; S Vincent Rajkumar; David Siegel; Marie-Laure Bravo; Marta Olesnyckyj; Robert D Knight; Jerome B Zeldis; Jean-Luc Harousseau; et al.
    Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone.
    Clinical lymphoma, myeloma & leukemia 2011;11(1):38-43.
  • 2011: Elena Díaz-Rodríguez; Stela Álvarez-Fernández; Xi Chen; Bruno Paiva; Ricardo López-Pérez; Juan Luis García-Hernández; Jesús F San Miguel; Atanasio Pandiella
    Deficient spindle assembly checkpoint in multiple myeloma.
    PloS one 2011;6(11):e27583.
  • 2011: Meletios A Dimopoulos; Maria-Victoria Mateos; Paul G Richardson; Rudolf Schlag; Nuriet K Khuageva; Ofer Shpilberg; Martin Kropff; Ivan Spicka; Antonio Palumbo; Ka Lung Wu; et al.
    Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study.
    European journal of haematology 2011;86(1):23-31.
  • 2010: Enrique M Ocio; Jesús F San Miguel
    The DAC system and associations with multiple myeloma.
    Investigational new drugs 2010;28 Suppl 1():S28-35.
  • 2010: Jean-Luc Harousseau; Antonio Palumbo; Paul G Richardson; Rudolf Schlag; Meletios A Dimopoulos; Ofer Shpilberg; Martin Kropff; Alain Kentos; Michele Cavo; Anatoly Golenkov; et al.
    Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone.
    Blood 2010;116(19):3743-50.
  • 2010: Jesús F San-Miguel
    Concluding remarks and future directions.
    Blood reviews 2010;24 Suppl 1():S33-4.
  • 2010: Jesús F San-Miguel
    Long-term disease control in multiple myeloma: the impact of the dual mechanism of action of lenalidomide. Introduction and overview.
    Blood reviews 2010;24 Suppl 1():S1-3.
  • 2010: Michel Delforge; Joan Bladé; Meletios A Dimopoulos; Thierry Facon; Martin Kropff; Heinz Ludwig; Antonio Palumbo; Philip Van Damme; Jesús F San-Miguel; Pieter Sonneveld
    Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues.
    The lancet oncology 2010;11(11):1086-95.
  • 2010: Juan José Lahuerta; Maria Victoria Mateos; Joaquin Martínez-López; Carlos Grande; Javier de la Rubia; Laura Rosiñol; Anna Sureda; José García-Laraña; Joaquín Díaz-Mediavilla; Miguel T Hernández-García; et al.
    Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study.
    Haematologica 2010;95(11):1913-20.
  • 2010: Lucía López-Corral; Ramón García-Sanz; Jesús F San Miguel
    [Value of serum free light chains assay in plasma cell disorders].
    Medicina clínica 2010;135(8):368-74.
  • 2010: Maria-Victoria Mateos; Paul G Richardson; Rudolf Schlag; Nuriet K Khuageva; Meletios A Dimopoulos; Ofer Shpilberg; Martin Kropff; Ivan Spicka; Maria T Petrucci; Antonio Palumbo; et al.
    Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(13):2259-66.
  • 2010: María Carmen Chillón; Carlos Santamaría; Ramón García-Sanz; Ana Balanzategui; María Eugenia Sarasquete; Miguel Alcoceba; Luis Marín; María Dolores Caballero; María Belén Vidriales; Fernando Ramos; et al.
    Long FLT3 internal tandem duplications and reduced PML-RARα expression at diagnosis characterize a high-risk subgroup of acute promyelocytic leukemia patients.
    Haematologica 2010;95(5):745-51.
  • 2010: Enrique M Ocio; David Vilanova; Peter Atadja; Patricia Maiso; Edvan Crusoe; Diego Fernández-Lázaro; Mercedes Garayoa; Laura San-Segundo; Teresa Hernández-Iglesias; Enrique de Alava; et al.
    In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma.
    Haematologica 2010;95(5):794-803.
  • 2010: Lucía López-Anglada; Norma C Gutiérrez; Juan L García; María V Mateos; Teresa Flores; Jesús F San Miguel
    P53 deletion may drive the clinical evolution and treatment response in multiple myeloma.
    European journal of haematology 2010;84(4):359-61.
  • 2010: N C Gutiérrez; M E Sarasquete; I Misiewicz-Krzeminska; M Delgado; J De Las Rivas; F V Ticona; E Fermiñán; P Martín-Jiménez; C Chillón; A Risueño; et al.
    Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling.
    Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2010;24(3):629-37.
  • 2010: Ernesto Pérez-Persona; Gema Mateo; Ramón García-Sanz; María-Victoria Mateos; Natalia de Las Heras; Alfonso García de Coca; José M Hernández; Josefina Galende; Guillermo Martín-Nuñez; Abelardo Bárez; et al.
    Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells.
    British journal of haematology 2010;148(1):110-4.
  • 2010: Fermin M Sanchez-Guijo; Enrique Oterino; Maria-Victoria Barbado; Soraya Carrancio; Natalia Lopez-Holgado; Sandra Muntion; Pilar Hernandez-Campo; Luis-Ignacio Sanchez-Abarca; Jose A Perez-Simon; Jesús F San Miguel; et al.
    Both CD133(+) cells and monocytes provide significant improvement for hindlimb ischemia, although they do not transdifferentiate into endothelial cells.
    Cell transplantation 2010;19(1):103-12.
  • 2009: Meletios A Dimopoulos; Paul G Richardson; Rudolf Schlag; Nuriet K Khuageva; Ofer Shpilberg; Efstathios Kastritis; Martin Kropff; Maria T Petrucci; Michel Delforge; Julia Alexeeva; et al.
    VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(36):6086-93.
  • 2009: P Maiso; E Colado; E M Ocio; M Garayoa; J Martín; P Atadja; A Pandiella; J F San-Miguel
    The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair.
    Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2009;23(12):2265-74.
  • 2009: Jesús F San Miguel
    Relapse/Refractory myeloma patient: potential treatment guidelines.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(34):5676-7.
  • 2009: Carlos M Santamaría; Maria C Chillón; Ramón García-Sanz; Cristina Pérez; María D Caballero; Fernando Ramos; Alfonso García de Coca; José M Alonso; Pilar Giraldo; Teresa Bernal; et al.
    High FOXO3a expression is associated with a poorer prognosis in AML with normal cytogenetics.
    Leukemia research 2009;33(12):1706-9.
  • 2009: Bruno Paiva; Maria-Belén Vidriales; Gema Mateo; Jose J Pérez; Maria Angeles Montalbán; Anna Sureda; Laura Montejano; Norma C Gutiérrez; Alfonso García de Coca; Natalia de las Heras; et al.
    The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients.
    Blood 2009;114(20):4369-72.
  • 2009: Fernanda N Villanueva; Jose Antonio Pérez-Simón; Fernando F Silva; Teresa T Caballero-Velázquez; Fermin F Sánchez-Guijo; Conzuelo C Cañizo; Lourdes L Vázquez; Dolores D Caballero; Jesús F San Miguel
    Oral beclomethasone dipropionate for the treatment of gastrointestinal chronic graft-versus-host disease.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2009;15(10):1331-6.
  • 2009: M Garayoa; J L Garcia; C Santamaria; A Garcia-Gomez; J F Blanco; A Pandiella; J M Hernández; F M Sanchez-Guijo; M-C del Cañizo; N C Gutiérrez; et al.
    Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors.
    Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2009;23(8):1515-27.
  • 2009: Carlos M Santamaría; María C Chillón; Ramón García-Sanz; Cristina Pérez; María D Caballero; Fernando Ramos; Alfonso García de Coca; José M Alonso; Pilar Giraldo; Teresa Bernal; et al.
    Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia.
    Blood 2009;114(1):148-52.
  • 2009: Belén Blanco; José A Pérez-Simón; Luis I Sánchez-Abarca; Teresa Caballero-Velazquez; Silvia Gutierrez-Cossío; Pilar Hernández-Campo; María Díez-Campelo; Carmen Herrero-Sanchez; Concepción Rodriguez-Serrano; Carlos Santamaría; et al.
    Treatment with bortezomib of human CD4+ T cells preserves natural regulatory T cells and allows the emergence of a distinct suppressor T-cell population.
    Haematologica 2009;94(7):975-83.
  • 2009: Edward A Stadtmauer; Donna M Weber; Ruben Niesvizky; Andrew Belch; Miles H Prince; Jesús F San Miguel; Thierry Facon; Marta Olesnyckyj; Zhinuan Yu; Jerome B Zeldis; et al.
    Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma.
    European journal of haematology 2009;82(6):426-32.
  • 2009: Enrique M Ocio; Patricia Maiso; Xi Chen; Mercedes Garayoa; Stela Alvarez-Fernández; Laura San-Segundo; David Vilanova; Lucía López-Corral; Juan C Montero; Teresa Hernández-Iglesias; et al.
    Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks.
    Blood 2009;113(16):3781-91.
  • 2009: O Lopez-Villar; J L Garcia; F M Sanchez-Guijo; C Robledo; E M Villaron; P Hernández-Campo; N Lopez-Holgado; M Diez-Campelo; M V Barbado; J A Perez-Simon; et al.
    Both expanded and uncultured mesenchymal stem cells from MDS patients are genomically abnormal, showing a specific genetic profile for the 5q- syndrome.
    Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2009;23(4):664-72.
  • 2009: José Angel Hernández; Ana Eugenia Rodríguez; Marcos González; Rocío Benito; Celia Fontanillo; Virgilio Sandoval; Mercedes Romero; Guillermo Martín-Núñez; Alfonso García de Coca; Rosa Fisac; et al.
    A high number of losses in 13q14 chromosome band is associated with a worse outcome and biological differences in patients with B-cell chronic lymphoid leukemia.
    Haematologica 2009;94(3):364-71.
  • 2009: Jesús F San-Miguel; María-Victoria Mateos
    How to treat a newly diagnosed young patient with multiple myeloma.
    Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2009;():555-65.
  • 2008: Juan José Lahuerta; Maria Victoria Mateos; Joaquin Martínez-López; Laura Rosiñol; Anna Sureda; Javier de la Rubia; José García-Laraña; Rafael Martínez-Martínez; Miguel T Hernández-García; Dolores Carrera; et al.
    Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(35):5775-82.
  • 2008: Joan Bladé; Pieter Sonneveld; Jesús F San Miguel; Heather J Sutherland; Roman Hajek; Arnon Nagler; Andrew Spencer; Tadeusz Robak; M Teresa Cibeira; Sen H Zhuang; et al.
    Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment.
    Clinical lymphoma & myeloma 2008;8(6):352-5.
  • 2008: Enrique M Ocio; María-Victoria Mateos; Patricia Maiso; Atanasio Pandiella; Jesús F San-Miguel
    New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings.
    The lancet oncology 2008;9(12):1157-65.
  • 2008: Carlos Santamaría; María Carmen Chillón; Ramón García-Sanz; Ana Balanzategui; María Eugenia Sarasquete; Miguel Alcoceba; Fernando Ramos; Teresa Bernal; José Antonio Queizán; María Jesús Peñarrubia; et al.
    The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia.
    Haematologica 2008;93(12):1797-805.
  • 2008: Bruno Paiva; Maria-Belén Vidriales; Jorge Cerveró; Gema Mateo; Jose J Pérez; Maria A Montalbán; Anna Sureda; Laura Montejano; Norma C Gutiérrez; Alfonso García de Coca; et al.
    Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.
    Blood 2008;112(10):4017-23.
  • 2008: Stephanie J Lee; Paul G Richardson; Pieter Sonneveld; Michael W Schuster; David Irwin; Jesús-F San Miguel; Bruce Crawford; Joseph Massaro; Ravinder Dhawan; Sanjay Gupta; et al.
    Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study.
    British journal of haematology 2008;143(4):511-9.
  • 2008: Miguel Alcoceba; Ana Balanzategui; Maria Díez-Campelo; Patricia Martín-Jiménez; Maria Eugenia Sarasquete; M Carmen Chillón; Carlos Santamaría; Jose Antonio Pérez-Simón; Luis Marín; M Dolores Caballero; et al.
    Clinical and prognostic value of discrepancies in microsatellite DNA regions between recipient and donor in human leukocyte antigen-identical allogeneic transplantation setting.
    Transplantation 2008;86(7):983-90.
  • 2008: Francis Ayuk; José A Perez-Simon; Avichai Shimoni; Anna Sureda; Tatjana Zabelina; Rainer Schwerdtfeger; Rodrigo Martino; Herbert Gottfried Sayer; Adrián Alegre; Juan-José Lahuerta; et al.
    Clinical impact of human Jurkat T-cell-line-derived antithymocyte globulin in multiple myeloma patients undergoing allogeneic stem cell transplantation.
    Haematologica 2008;93(9):1343-50.
  • 2008: Soraya Tabera; José A Pérez-Simón; María Díez-Campelo; Luis I Sánchez-Abarca; Belén Blanco; Antonio López; Ana Benito; Enrique Ocio; Fermín M Sánchez-Guijo; Consuelo Cañizo; et al.
    The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B-lymphocytes.
    Haematologica 2008;93(9):1301-9.
  • 2008: Jesús F San Miguel; Rudolf Schlag; Nuriet K Khuageva; Meletios A Dimopoulos; Ofer Shpilberg; Martin Kropff; Ivan Spicka; Maria T Petrucci; Antonio Palumbo; Olga S Samoilova; et al.
    Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
    The New England journal of medicine 2008;359(9):906-17.
  • 2008: Soraya Carrancio; Natalia López-Holgado; Fermín M Sánchez-Guijo; Eva Villarón; Victoria Barbado; Soraya Tabera; María Díez-Campelo; Juan Blanco; Jesús F San Miguel; M Consuelo Del Cañizo
    Optimization of mesenchymal stem cell expansion procedures by cell separation and culture conditions modification.
    Experimental hematology 2008;36(8):1014-21.
  • 2008: Jose A Pérez-Simón; Rodrigo Martino; Dolores Caballero; David Valcarcel; Noemi Rebollo; Rafael de la Cámara; Javier Pérez de Oteiza; Inmaculada Heras; Maria V Calvo; Jordi Sierra; et al.
    Reduced-intensity conditioning allogeneic transplantation from unrelated donors: evaluation of mycophenolate mofetil plus cyclosporin A as graft-versus-host disease prophylaxis.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2008;14(6):664-71.
  • 2008: Gema Mateo; M Angeles Montalbán; Maria-Belén Vidriales; Juan J Lahuerta; Maria V Mateos; Norma Gutiérrez; Laura Rosiñol; Laura Montejano; Joan Bladé; Rafael Martínez; et al.
    Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(16):2737-44.
  • 2008: Juan Carlos Montero; Ricardo López-Pérez; Jesús F San Miguel; Atanasio Pandiella
    Expression of c-Kit isoforms in multiple myeloma: differences in signaling and drug sensitivity.
    Haematologica 2008;93(6):851-9.
  • 2008: M Alcoceba; L Marín; A Balanzategui; M E Sarasquete; P Martín-Jiménez; M C Chillón; R Corral; E Pérez-Persona; F J Fernández-Calvo; J M Hernández; et al.
    The presence of DRB1*01 allele in multiple myeloma patients is associated with an indolent disease.
    Tissue antigens 2008;71(6):548-51.
  • 2008: Patricia Maiso; Enrique M Ocio; Mercedes Garayoa; Juan C Montero; Francesco Hofmann; Carlos García-Echeverría; Johann Zimmermann; Atanasio Pandiella; Jesús F San Miguel
    The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells.
    British journal of haematology 2008;141(4):470-82.
  • 2008: María-Victoria Mateos; José M Hernández; Miguel T Hernández; Norma C Gutiérrez; Luis Palomera; Marta Fuertes; Pedro Garcia-Sanchez; Juán J Lahuerta; Javier de la Rubia; María-José Terol; et al.
    Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
    Haematologica 2008;93(4):560-5.
  • 2008: J F San-Miguel; P G Richardson; P Sonneveld; M W Schuster; D Irwin; E A Stadtmauer; T Facon; J-L Harousseau; D Ben-Yehuda; S Lonial; et al.
    Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study.
    Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2008;22(4):842-9.
  • 2008: Marta Martín-Ayuso; Julia Almeida; Martín Pérez-Andrés; Rebeca Cuello; Josefina Galende; Maria Isabel González-Fraile; Guillermo Martín-Nuñez; Fernando Ortega; Maria Jesús Rodríguez; Jesús F San Miguel; et al.
    Peripheral blood dendritic cell subsets from patients with monoclonal gammopathies show an abnormal distribution and are functionally impaired.
    The oncologist 2008;13(1):82-92.
  • 2008: Enrique Colado; Stela Alvarez-Fernández; Patricia Maiso; Jesús Martín-Sánchez; Maria Belén Vidriales; Mercedes Garayoa; Enrique M Ocio; Juan Carlos Montero; Atanasio Pandiella; Jesús F San Miguel
    The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype.
    Haematologica 2008;93(1):57-66.
  • 2007: M V Mateos; J F San Miguel
    Bortezomib in multiple myeloma.
    Best practice & research. Clinical haematology 2007;20(4):701-15.
  • 2007: Patricia Martín-Jiménez; Ramón García-Sanz; David González; Ana Balanzategui; José J Pérez; M Dolores Caballero; M Eugenia Sarasquete; Josefina Galende; Alberto Orfao; M Consuelo López-Berges; et al.
    Molecular characterization of complete and incomplete immunoglobulin heavy chain gene rearrangements in hairy cell leukemia.
    Clinical lymphoma & myeloma 2007;7(9):573-9.
  • 2007: David González; Mirjam van der Burg; Ramón García-Sanz; James A Fenton; Anton W Langerak; Marcos González; Jacques J M van Dongen; Jesus F San Miguel; Gareth J Morgan
    Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma.
    Blood 2007;110(9):3112-21.
  • 2007: E M Villaron; J Almeida; N Lopez-Holgado; F M Sanchez-Guijo; M Alberca; B Blanco; L I Sanchez-Abarca; O Lopez; J A Perez-Simon; J F San Miguel; et al.
    In leukapheresis products from non-Hodgkin's lymphoma patients, the immature hematopoietic progenitors show higher CD90 and CD34 antigenic expression.
    Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis 2007;37(2):145-56.
  • 2007: Ernesto Pérez-Persona; María-Belén Vidriales; Gema Mateo; Ramón García-Sanz; Maria-Victoria Mateos; Alfonso García de Coca; Josefina Galende; Guillermo Martín-Nuñez; José M Alonso; Natalia de Las Heras; et al.
    New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells.
    Blood 2007;110(7):2586-92.
  • 2007: José Bagán; Juan Blade; Jose Manuel Cozar; Manuel Constela; Ramón García Sanz; Francisco Gómez Veiga; Juan José Lahuerta; Ana Lluch; Bartomeu Massuti; Juan Morote; et al.
    Recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates.
    Medicina oral, patología oral y cirugía bucal 2007;12(4):E336-40.
  • 2007: Ramón García-Sanz; María Victoria Mateos; Jesús Fernando San Miguel
    [Multiple myeloma].
    Medicina clínica 2007;129(3):104-15.
  • 2007: Paul G Richardson; Pieter Sonneveld; Michael W Schuster; David Irwin; Edward A Stadtmauer; Thierry Facon; Jean-Luc Harousseau; Dina Ben-Yehuda; Sagar Lonial; Jesús-F San Miguel; et al.
    Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma.
    British journal of haematology 2007;137(5):429-35.
  • 2007: J M Ramirez; E M Ocio; J F San Miguel; A Pandiella
    Pemetrexed acts as an antimyeloma agent by provoking cell cycle blockade and apoptosis.
    Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2007;21(4):797-804.
  • 2007: Carlos Santamaría; Maria Carmen Chillón; Carina Fernández; Patricia Martín-Jiménez; Ana Balanzategui; Ramón García Sanz; Jesús F San Miguel; Marcos-Gonzalez González
    Using quantification of the PML-RARalpha transcript to stratify the risk of relapse in patients with acute promyelocytic leukemia.
    Haematologica 2007;92(3):315-22.
  • 2007: N C Gutiérrez; E M Ocio; J de Las Rivas; P Maiso; M Delgado; E Fermiñán; M J Arcos; M L Sánchez; J M Hernández; J F San Miguel
    Gene expression profiling of B lymphocytes and plasma cells from Waldenström's macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals.
    Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2007;21(3):541-9.
  • 2007: N López-Holgado; M Alberca; F Sánchez-Guijo; E Villarón; J Almeida; A Martín; A Armellini; C García; B Blanco; I Sánchez-Abarca; et al.
    Short-term endothelial progenitor cell colonies are composed of monocytes and do not acquire endothelial markers.
    Cytotherapy 2007;9(1):14-22.
  • 2007: E M Ocio; R F J Schop; B Gonzalez; S A Van Wier; J M Hernandez-Rivas; N C Gutierrez; R Garcia-Sanz; M J Moro; C Aguilera; J Hernandez; et al.
    6q deletion in Waldenström macroglobulinemia is associated with features of adverse prognosis.
    British journal of haematology 2007;136(1):80-6.
  • 2007: Patricia Martín-Jiménez; Ramón García-Sanz; María E Sarasquete; Enrique Ocio; José J Pérez; Marcos González; Jesús F San Miguel
    Functional class switch recombination may occur 'in vivo' in Waldenström macroglobulinaemia.
    British journal of haematology 2007;136(1):114-6.
  • 2007: N C Gutiérrez; M V Castellanos; M L Martín; M V Mateos; J M Hernández; M Fernández; D Carrera; L Rosiñol; J M Ribera; J M Ojanguren; et al.
    Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis.
    Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2007;21(1):143-50.
  • 2007: J R Gonzalez-Porras; F Martin-Herrero; R Garcia-Sanz; M L Lopez; A Balanzategui; M V Mateos; P Pavon; M Gonzalez; I Alberca; J F San Miguel
    Hyperhomocysteinemia is a risk factor of recurrent coronary event in young patients irrespective to the MTHFR C677T polymorphism.
    Thrombosis research 2007;119(6):691-8.
  • 2006: R García-Sanz; J M Hernández; A Sureda; J García-Laraña; F Prósper; A Alegre; A Bárez; M V Mateos; J F San Miguel
    Pegylated liposomal doxorubicin, melphalan and prednisone therapy for elderly patients with multiple myeloma.
    Hematological oncology 2006;24(4):205-11.
  • 2006: Ignacio Garcia Escobar; Dolores Caballero Barrigon; Pilar Tamayo; Jose Antonio Perez-Simon; Maria Vitoria Mateos; Jose Ramon Garcia; Jesus F San Miguel
    Prognostic impact of pretransplantation computed tomography and gallium scans in patients with Hodgkin lymphoma with poor prognosis undergoing hematopoietic stem cell transplantation.
    Clinical lymphoma & myeloma 2006;7(3):217-25.
  • 2006: María Eugenia Sarasquete; Ramón García-Sanz; Adriana Armellini; Marta Fuertes; Patricia Martín-Jiménez; Magdalena Sierra; María Del Carmen Chillón; Miguel Alcoceba; Ana Balanzategui; Fernando Ortega; et al.
    The association of increased p14ARF/p16INK4a and p15INK4a gene expression with proliferative activity and the clinical course of multiple myeloma.
    Haematologica 2006;91(11):1551-4.
  • 2006: María-Victoria Mateos; José-M Hernández; Miguel-T Hernández; Norma-C Gutiérrez; Luis Palomera; Marta Fuertes; Joaquín Díaz-Mediavilla; Juan-J Lahuerta; Javier de la Rubia; María-José Terol; et al.
    Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study.
    Blood 2006;108(7):2165-72.
  • 2006: C Castilla; J A Pérez-Simón; F M Sanchez-Guijo; M Díez-Campelo; E Ocio; E Pérez-Persona; O López-Villar; L Vazquez; D Caballero; J F San Miguel
    Oral beclomethasone dipropionate for the treatment of gastrointestinal acute graft-versus-host disease (GVHD).
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2006;12(9):936-41.
  • 2006: Magdalena Sierra; Alvaro Alonso; M Dolores Odero; M Belén Gonzalez; Idoia Lahortiga; José J Pérez; Juan L García; Norma C Gutiérrez; María J Calasanz; Jesús F San Miguel; et al.
    Geographic differences in the incidence of cytogenetic abnormalities of acute myelogenous leukemia (AML) in Spain.
    Leukemia research 2006;30(8):943-8.
  • 2006: Jesús F San Miguel; Norma C Gutiérrez; Gema Mateo; Alberto Orfao
    Conventional diagnostics in multiple myeloma.
    European journal of cancer (Oxford, England : 1990) 2006;42(11):1510-9.
  • 2006: Luis Ramos; José Antonio de Las Heras; Sergio Sánchez; José Ramón González-Porras; Rafael González; Maria Victoria Mateos; Jesús F San Miguel
    Medium-term results of percutaneous vertebroplasty in multiple myeloma.
    European journal of haematology 2006;77(1):7-13.
  • 2006: N W C J van de Donk; N Kröger; U Hegenbart; P Corradini; J F San Miguel; H Goldschmidt; J A Perez-Simon; M Zijlmans; R A Raymakers; V Montefusco; et al.
    Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma.
    Bone marrow transplantation 2006;37(12):1135-41.
  • 2006: Patricia Maiso; Xonia Carvajal-Vergara; Enrique M Ocio; Ricardo López-Pérez; Gema Mateo; Norma Gutiérrez; Peter Atadja; Atanasio Pandiella; Jesús F San Miguel
    The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.
    Cancer research 2006;66(11):5781-9.
  • 2006: Niels W C J van de Donk; Nicolaus Kröger; Ute Hegenbart; Paolo Corradini; Jesus F San Miguel; Hartmut Goldschmidt; Jose A Perez-Simon; Mark Zijlmans; Reinier A Raymakers; Vittorio Montefusco; et al.
    Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma.
    Blood 2006;107(8):3415-6.
  • 2006: Martin Pérez-Andres; Julia Almeida; Marta Martin-Ayuso; Maria Jesus Moro; Guillermo Martin-Nuñez; Josefina Galende; Jose Hernandez; Gema Mateo; Jesus F San Miguel; Alberto Orfao; et al.
    Characterization of bone marrow T cells in monoclonal gammopathy of undetermined significance, multiple myeloma, and plasma cell leukemia demonstrates increased infiltration by cytotoxic/Th1 T cells demonstrating a squed TCR-Vbeta repertoire.
    Cancer 2006;106(6):1296-305.
  • 2006: Maria Luz Sanchez; Julia Almeida; Antonio Lopez; Jose Maria Sayagues; Ana Rasillo; Eugenia A Sarasquete; Ana Balanzategui; Maria Dolores Tabernero; Joaquin Diaz-Mediavilla; Carmen Barrachina; et al.
    Heterogeneity of neoplastic cells in B-cell chronic lymphoproliferative disorders: biclonality versus intraclonal evolution of a single tumor cell clone.
    Haematologica 2006;91(3):331-9.
  • 2006: J A Pérez-Simón; A Sureda; F Fernández-Aviles; A Sampol; J R Cabrera; D Caballero; R Martino; J Petit; J F Tomás; J M Moraleda; et al.
    Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients.
    Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2006;20(3):542-5.
  • 2006: J Mateos; J A Pérez-Simón; D Caballero; C Castilla; O Lopez; E Perez; C Cañizo; L Vazquez; J F San Miguel
    Vincristine is an effective therapeutic approach for transplantation-associated thrombotic microangiopathy.
    Bone marrow transplantation 2006;37(3):337-8.
  • 2006: Eva M Villaron; Jose Antonio Perez-Simon; Jesus F San Miguel; Consuelo del Cañizo
    Bone marrow mesenchymal stem cells chimerism after allogeneic hematopoietic transplantation.
    Experimental hematology 2006;34(1):7.
  • 2005: L Vazquez; J J Mateos; C Sanz-Rodriguez; E Perez; D Caballero; J F San Miguel
    Successful treatment of rhinocerebral zygomycosis with a combination of caspofungin and liposomal amphotericin B.
    Haematologica 2005;90(12 Suppl):ECR39.
  • 2005: María Eugenia Sarasquete; Ramón García-Sanz; David González; Joaquín Martínez; Gema Mateo; Pilar Martínez; José Maria Ribera; José Mariano Hernández; Juan José Lahuerta; Alberto Orfão; et al.
    Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry.
    Haematologica 2005;90(10):1365-72.
  • 2005: Agnes Fütterer; Miguel R Campanero; Esther Leonardo; Luis M Criado; Juana M Flores; Jesús M Hernández; Jesús F San Miguel; Carlos Martínez-A
    Dido gene expression alterations are implicated in the induction of hematological myeloid neoplasms.
    The Journal of clinical investigation 2005;115(9):2351-62.
  • 2005: José A Pérez-Simón; María Díez-Campelo; Rodrigo Martino; Salut Brunet; Alvaro Urbano; María D Caballero; Angel de León; David Valcárcel; Enric Carreras; María C del Cañizo; et al.
    Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation.
    British journal of haematology 2005;130(3):394-403.
  • 2005: Fermin M Sanchez-Guijo; Luis-Ignacio Sanchez-Abarca; Eva Villaron; Natalia Lopez-Holgado; Mercedes Alberca; Lourdes Vazquez; Jose A Perez-Simon; Jesus Lopez-Fidalgo; Alberto Orfao; Maria-Dolores Caballero; et al.
    Posttransplant hematopoiesis in patients undergoing sibling allogeneic stem cell transplantation reflects that of their respective donors although with a lower functional capability.
    Experimental hematology 2005;33(8):935-43.
  • 2005: David González; Marcos González; Ana Balanzategui; Maria E Sarasquete; Ricardo López-Pérez; M Carmen Chillón; Ramón García-Sanz; Jesús F San Miguel
    Molecular characteristics and gene segment usage in IGH gene rearrangements in multiple myeloma.
    Haematologica 2005;90(7):906-13.
  • 2005: Magdalena Sierra; Jesús M Hernández; Juan L García; Norma C Gutiérrez; José J Pérez; M Belén Vidriales; Fernando Ramos; José M Hernández; Mercedes Romero; M Belén González; et al.
    Hematological, immunophenotypic, and cytogenetic characteristics of acute myeloblastic leukemia with trisomy 11.
    Cancer genetics and cytogenetics 2005;160(1):68-72.
  • 2005: Paul G Richardson; Pieter Sonneveld; Michael W Schuster; David Irwin; Edward A Stadtmauer; Thierry Facon; Jean-Luc Harousseau; Dina Ben-Yehuda; Sagar Lonial; Hartmut Goldschmidt; et al.
    Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.
    The New England journal of medicine 2005;352(24):2487-98.
  • 2005: Rodrigo Martino; José A Pérez-Simón; Estela Moreno; José M Queraltó; Dolores Caballero; Marivi Mateos; Anna Sureda; Consuelo Cañizo; Salut Brunet; Javier Briones; et al.
    Reduced-intensity conditioning allogeneic blood stem cell transplantation with fludarabine and oral busulfan with or without pharmacokinetically targeted busulfan dosing in patients with myeloid leukemia ineligible for conventional conditioning.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2005;11(6):437-47.
  • 2005: J M Hernández; C Castilla; N C Gutiérrez; I M Isidro; M Delgado; J de las Rivas; E Fermiñán; J L García; E M Ocio; M C del Cañizo; et al.
    Mobilisation with G-CSF in healthy donors promotes a high but temporal deregulation of genes.
    Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2005;19(6):1088-91.
  • 2005: Xonia Carvajal-Vergara; Soraya Tabera; Juan C Montero; Azucena Esparís-Ogando; Ricardo López-Pérez; Gema Mateo; Norma Gutiérrez; Marisa Parmo-Cabañas; Joaquín Teixidó; Jesús F San Miguel; et al.
    Multifunctional role of Erk5 in multiple myeloma.
    Blood 2005;105(11):4492-9.
  • 2005: Gema Mateo; Mariana Castellanos; Ana Rasillo; Norma C Gutiérrez; Ma Angeles Montalbán; Ma Luisa Martín; Jesús Ma Hernández; Ma Consuelo López-Berges; Laura Montejano; Joan Bladé; et al.
    Genetic abnormalities and patterns of antigenic expression in multiple myeloma.
    Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(10):3661-7.
  • 2005: Fermin M Sanchez-Guijo; Luis-Ignacio Sanchez-Abarca; Clara Bueno; Eva Villaron; Natalia Lopez-Holgado; Lourdes Vazquez; Jesus Lopez-Fidalgo; Jose A Perez-Simon; Maria-Dolores Caballero; Maria-Consuelo del Cañizo; et al.
    Long-term immune recovery of patients undergoing allogeneic stem cell transplantation: a comparison with their respective sibling donors.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2005;11(5):354-61.
  • 2005: D Primo; M D Tabernero; J J Perez; A Rasillo; J M Sayagués; A B Espinosa; M C Lopez-Berges; R García-Sanz; N C Gutierrez; J M Hernandez; et al.
    Genetic heterogeneity of BCR/ABL+ adult B-cell precursor acute lymphoblastic leukemia: impact on the clinical, biological and immunophenotypical disease characteristics.
    Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2005;19(5):713-20.
  • 2005: Azucena Esparís-Ogando; Adrián Alegre; Beatriz Aguado; Gema Mateo; Norma Gutiérrez; Joan Bladé; David Schenkein; Atanasio Pandiella; Jesús F San Miguel
    Bortezomib is an efficient agent in plasma cell leukemias.
    International journal of cancer. Journal international du cancer 2005;114(4):665-7.
  • 2005: Enrique M Ocio; Fermin M Sanchez-Guijo; Maria Diez-Campelo; Cristina Castilla; Oscar J Blanco; Dolores Caballero; Jesus F San Miguel
    Efficacy of rituximab in an aggressive form of multicentric Castleman disease associated with immune phenomena.
    American journal of hematology 2005;78(4):302-5.
  • 2005: Enrique M Ocio; Gema Mateo; Belen Vidriales; M Consuelo Lopez-Berges; Ramon Garcia-Sanz; Jesus M Hernandez; Alberto Orfao; Jesus F San Miguel
    Cell cycle analysis of Waldenstrom's macroglobulinemia.
    Clinical lymphoma 2005;5(4):250-2.
  • 2005: Enrique M Ocio; Jesus M Hernandez; Gema Mateo; Maria L Sanchez; Belen Gonzalez; Belen Vidriales; Norma C Gutierrez; Alberto Orfao; Jesus F San Miguel
    Immunophenotypic and cytogenetic comparison of Waldenstrom's macroglobulinemia with splenic marginal zone lymphoma.
    Clinical lymphoma 2005;5(4):241-5.
  • 2005: Natalia López-Holgado; Carmen Pata; Eva Villarón; Fermín Sánchez-Guijo; Mercedes Alberca; Alejandro Martín; Mercedes Corral; Ignacio Sánchez-Abarca; Josè Antonio Pérez-Simón; Jesús Fernando San Miguel; et al.
    Long-term bone marrow culture data are the most powerful predictor of peripheral blood progenitor cell mobilization in healthy donors.
    Haematologica 2005;90(3):353-9.
  • 2005: M Pérez-Andrés; J Almeida; M Martín-Ayuso; M J Moro; G Martín-Nuñez; J Galende; D Borrego; M J Rodríguez; F Ortega; J Hernandez; et al.
    Clonal plasma cells from monoclonal gammopathy of undetermined significance, multiple myeloma and plasma cell leukemia show different expression profiles of molecules involved in the interaction with the immunological bone marrow microenvironment.
    Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2005;19(3):449-55.
  • 2005: N C Gutiérrez; R López-Pérez; J M Hernández; I Isidro; B González; M Delgado; E Fermiñán; J L García; L Vázquez; M González; et al.
    Gene expression profile reveals deregulation of genes with relevant functions in the different subclasses of acute myeloid leukemia.
    Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2005;19(3):402-9.
  • 2005: M Díez-Campelo; J A Pérez-Simón; E M Ocio; C Castilla; J R González-Porras; F M Sánchez-Guijo; L Vázquez; M D Caballero; M C Cañizo; J F San Miguel
    CD34 + cell dose and outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation.
    Leukemia & lymphoma 2005;46(2):177-83.
  • 2005: Jesús F San Miguel; Ramón García-Sanz
    Prognostic features of multiple myeloma.
    Best practice & research. Clinical haematology 2005;18(4):569-83.
  • 2005: Alejandro Martín; Josè Antonio Pérez-Simón; Maria Dolores Caballero; Natalia López-Holgado; Lourdes Vázquez; Maria Consuelo del Cañizo; Jesus F San Miguel
    Effect of pre-transplant cumulative doses of chemotherapeutic drugs on early and long-term hematological recovery after autologous bone-marrow transplantation for lymphoma.
    Haematologica 2005;90(1):78-85.
  • 2005: Lilia Suárez; María Belén Vidriales; María-José Moreno; Antonio López; José García-Laraña; Cristina Pérez-López; Mar Tormo; Esperanza Lavilla; María Consuelo López-Berges; María de Santiago; et al.
    Differences in anti-apoptotic and multidrug resistance phenotypes in elderly and young acute myeloid leukemia patients are related to the maturation of blast cells.
    Haematologica 2005;90(1):54-9.
  • 2004: R García-Sanz; M I González-Fraile; G Mateo; J M Hernández; M C López-Berges; N de las Heras; J Fernández-Calvo; F Ortega; J A Portero; A Bárez; et al.
    Proliferative activity of plasma cells is the most relevant prognostic factor in elderly multiple myeloma patients.
    International journal of cancer. Journal international du cancer 2004;112(5):884-9.
  • 2004: Eva María Villaron; Julia Almeida; Natalia López-Holgado; Miguel Alcoceba; Luis Ignacio Sánchez-Abarca; Fermin Martin Sanchez-Guijo; Mercedes Alberca; Jose Antonio Pérez-Simon; Jesus Fernando San Miguel; María Consuelo Del Cañizo
    Mesenchymal stem cells are present in peripheral blood and can engraft after allogeneic hematopoietic stem cell transplantation.
    Haematologica 2004;89(12):1421-7.
  • 2004: Natalia López-Holgado; Jose Luis Arroyo; Carmen Pata; Eva Villarón; Fermín Sánchez Guijo; Alejandro Martín; Jesús María Hernández Rivas; Alberto Orfao; Jesús Fernando San Miguel; M Consuelo Del Cañizo Fernández-Roldán
    Analysis of hematopoietic progenitor cells in patients with myelodysplastic syndromes according to their cytogenetic abnormalities.
    Leukemia research 2004;28(11):1181-7.
  • 2004: Norma C Gutiérrez; Juan L García; Jesús M Hernández; Eva Lumbreras; Mariana Castellanos; Ana Rasillo; Gema Mateo; José M Hernández; Sonia Pérez; Alberto Orfao; et al.
    Prognostic and biologic significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma.
    Blood 2004;104(9):2661-6.
  • 2004: M Belén González; Jesús M Hernández; Juan L García; Eva Lumbreras; Mariana Castellanos; José M Hernández; Javier Fernández-Calvo; Norma C Gutiérrez; Jesús F San Miguel
    The value of fluorescence in situ hybridization for the detection of 11q in multiple myeloma.
    Haematologica 2004;89(10):1213-8.
  • 2004: J M Hernández; R García-Sanz; E Golvano; J Bladé; J Fernandez-Calvo; J Trujillo; J A Soler; S Gardella; F Carbonell; G Mateo; et al.
    Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma.
    British journal of haematology 2004;127(2):159-64.
  • 2004: Nicolaus Kröger; Jose A Perez-Simon; Han Myint; Hans Klingemann; Avichai Shimoni; Arnon Nagler; Rodrigo Martino; Adrian Alegre; Jose F Tomas; Rainer Schwerdtfeger; et al.
    Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2004;10(10):698-708.
  • 2004: J A Pérez-Simón; D Caballero; M V Mateos; J F San Miguel
    Graft vs. host disease and graft vs. myeloma effect after non-myeloablative allogeneic transplantation.
    Leukemia & lymphoma 2004;45(9):1725-9.
  • 2004: M Pérez-Andrés; M Santiago; J Almeida; G Mateo; A Porwit-MacDonald; E Bjorklund; G Valet; J Kraan; J W Gratama; J L D'Hautcourt; et al.
    Immunophenotypic approach to the identification and characterization of clonal plasma cells from patients with monoclonal gammopathies.
    Journal of biological regulators and homeostatic agents 2004;18(3-4):392-8.
  • 2004: L Suárez; M B Vidriales; G Sanz; A López; M C López-Berges; M de Santiago; L Palomera; T Bernal; M E Pérez de Equiza; J F San Miguel; et al.
    Expression of APO2.7, bcl-2 and bax apoptosis-associated proteins in CD34- bone marrow cell compartments from patients with myelodysplastic syndromes.
    Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2004;18(7):1311-3.
  • 2004: Nicolaus Kröger; Georgia Schilling; Hermann Einsele; Peter Liebisch; Avichai Shimoni; Arnon Nagler; Jose A Perez-Simon; Jesus F San Miguel; Michael Kiehl; Axel Fauser; et al.
    Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation.
    Blood 2004;103(11):4056-61.
  • 2004: M Belén González; Norma C Gutiérrez; Juan L García; Eric F P M Schoenmakers; Francesc Solé; M José Calasanz; Jesús F San Miguel; Jesús M Hernández
    Heterogeneity of structural abnormalities in the 7q31.3 approximately q34 region in myeloid malignancies.
    Cancer genetics and cytogenetics 2004;150(2):136-43.
  • 2004: M Perez-Andres; J Almeida; M Martin-Ayuso; M J Moro; M A Garcia-Marcos; I Moreno; M Dominguez; J Galende; N Heras; M I Gonzalez; et al.
    Interaction between clonal plasma cells and the immune system in plasma cell dyscrasias.
    Journal of biological regulators and homeostatic agents 2004;18(2):161-5.
  • 2004: R García-Sanz; J R González-Porras; J M Hernández; M Polo-Zarzuela; A Sureda; C Barrenetxea; L Palomera; R López; C Grande-García; A Alegre; et al.
    The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma.
    Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2004;18(4):856-63.
  • 2004: A Martín; J-A Pérez-Simón; M D Caballero; N López; R García-Sanz; L Vázquez; M C del Cañizo; J F San Miguel
    Effect of cumulative etoposide doses on the outcome of autologous peripheral-blood progenitor-cell transplantation for lymphoma.
    Bone marrow transplantation 2004;33(6):579-87.
  • 2004: P Menendez; A Vargas; C Bueno; S Barrena; J Almeida; M De Santiago; A López; S Roa; J F San Miguel; A Orfao
    Quantitative analysis of bcl-2 expression in normal and leukemic human B-cell differentiation.
    Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2004;18(3):491-8.
  • 2004: José M Hernández; Begoña Suquía; José A Queizan; Rosa M Fisac; José J Sanchez; Francisco J Fernández-Calvo; Ramón García-Sanz; Carmen Olivier; Abelardo Bárez; María J Calmuntia; et al.
    Bone remodelation markers are useful in the management of monoclonal gammopathies.
    The hematology journal : the official journal of the European Haematology Association / EHA 2004;5(6):480-8.
  • 2004: Jose Luis Arroyo; Ma Eugenia Fernández; Jesús Maria Hernández; Alberto Orfao; Jesús Fernando San Miguel; Maria Consuelo del Cañizo
    Impact of immunophenotype on prognosis of patients with myelodysplastic syndromes. Its value in patients without karyotypic abnormalities.
    The hematology journal : the official journal of the European Haematology Association / EHA 2004;5(3):227-33.
  • 2004: Clara Bueno; Julia Almeida; Paulo Lucio; Josefa Marco; Raimundo Garcia; Jose Maria de Pablos; Antonio Parreira; Fernando Ramos; Francisco Ruiz-Cabello; Dimas Suarez-Vilela; et al.
    Incidence and characteristics of CD4(+)/HLA DRhi dendritic cell malignancies.
    Haematologica 2004;89(1):58-69.
  • 2004: J A Pérez-Simón; I García-Escobar; J Martinez; L Vazquez; D Caballero; C Cañizo; M V Mateos; J F San Miguel
    Antibiotic prophylaxis with meropenem after allogeneic stem cell transplantation.
    Bone marrow transplantation 2004;33(2):183-7.
  • 2003: José Rodriguez; Maria Dolores Caballero; Antonio Gutierrez; Marco Gandarillas; Jorge Sierra; Armando Lopez-Guillermo; Anna Sureda; Javier Zuazu; Jesus Marin; Reyes Arranz; et al.
    High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience.
    Haematologica 2003;88(12):1372-7.
  • 2003: Atanasio Pandiella; Xonia Carvajal-Vergara; Soraya Tabera; Gema Mateo; Norma Gutiérrez; Jesús F San Miguel
    Imatinib mesylate (STI571) inhibits multiple myeloma cell proliferation and potentiates the effect of common antimyeloma agents.
    British journal of haematology 2003;123(5):858-68.
  • 2003: María B Vidriales; Jesús F San-Miguel; Alberto Orfao; Elaine Coustan-Smith; Dario Campana
    Minimal residual disease monitoring by flow cytometry.
    Best practice & research. Clinical haematology 2003;16(4):599-612.
  • 2003: Maria-Luz Sanchez; Julia Almeida; David Gonzalez; Marcos Gonzalez; Maria-Antonia Garcia-Marcos; Ana Balanzategui; Maria-Consuelo Lopez-Berges; Josep Nomdedeu; Teresa Vallespi; Marcos Barbon; et al.
    Incidence and clinicobiologic characteristics of leukemic B-cell chronic lymphoproliferative disorders with more than one B-cell clone.
    Blood 2003;102(8):2994-3002.
  • 2003: J L García; J M Hernandez; N C Gutiérrez; T Flores; D González; M J Calasanz; J A Martínez-Climent; M A Piris; C Lopéz-Capitán; M B González; et al.
    Abnormalities on 1q and 7q are associated with poor outcome in sporadic Burkitt's lymphoma. A cytogenetic and comparative genomic hybridization study.
    Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2003;17(10):2016-24.
  • 2003: Juan L Garcia; Jaime Font de Mora; Jesus M Hernandez; Jose A Queizan; Norma C Gutierrez; Jose M Hernandez; Jesus F San Miguel
    Imatinib mesylate elicits positive clinical response in atypical chronic myeloid leukemia involving the platelet-derived growth factor receptor beta.
    Blood 2003;102(7):2699-700.
  • 2003: Gema Mateo; Mercedes Corral; Julia Almeida; Consuelo López-Berges; maría Jesús Nieto; Antonia García-Marcos; Lourdes Vázquez; Consuelo del Cañizo; Alberto Orfao; Jesús F San Miguel
    Immunophenotypic analysis of peripheral blood stem cell harvests from patients with multiple myeloma.
    Haematologica 2003;88(9):1013-21.
  • 2003: María-Belén Vidriales; Alberto Orfao; Jesús F San-Miguel
    Immunologic monitoring in adults with acute lymphoblastic leukemia.
    Current oncology reports 2003;5(5):413-8.
  • 2003: Margarida Lima; Julia Almeida; Maria Dos Anjos Teixeira; Maria del Carmen Alguero Md; Ana Helena Santos; Ana Balanzategui; Maria Luís Queirós; Paloma Bárcena; Antonio Izarra; Sónia Fonseca; et al.
    TCRalphabeta+/CD4+ large granular lymphocytosis: a new clonal T-cell lymphoproliferative disorder.
    The American journal of pathology 2003;163(2):763-71.
  • 2003: María-Belén Vidriales; José J Pérez; Maria Consuelo López-Berges; Norma Gutiérrez; Juana Ciudad; Paulo Lucio; Lourdes Vazquez; Ramón García-Sanz; Maria Consuelo del Cañizo; Javier Fernández-Calvo; et al.
    Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value.
    Blood 2003;101(12):4695-700.
  • 2003: D Primo; M D Tabernero; A Rasillo; J M Sayagués; A B Espinosa; M C Chillón; R Garcia-Sanz; N Gutierrez; M Giralt; A Hagemeijer; et al.
    Patterns of BCR/ABL gene rearrangements by interphase fluorescence in situ hybridization (FISH) in BCR/ABL+ leukemias: incidence and underlying genetic abnormalities.
    Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2003;17(6):1124-9.
  • 2003: D González; M González; M E Alonso; R López-Pérez; A Balanzategui; M C Chillón; M Silva; R García-Sanz; J F San Miguel
    Incomplete DJH rearrangements as a novel tumor target for minimal residual disease quantitation in multiple myeloma using real-time PCR.
    Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2003;17(6):1051-7.
  • 2003: Jesús F San Miguel; Ramón García-Sanz
    Myeloma: update on supportive care strategies.
    Current treatment options in oncology 2003;4(3):247-58.
  • 2003: J F San Miguel; M B Vidriales; E Ocio; G Mateo; F Sánchez-Guijo; M L Sánchez; L Escribano; A Bárez; M J Moro; J Hernández; et al.
    Immunophenotypic analysis of Waldenstrom's macroglobulinemia.
    Seminars in oncology 2003;30(2):187-95.
  • 2003: Roger G Owen; Steven P Treon; Ayad Al-Katib; Rafael Fonseca; Philip R Greipp; Mary L McMaster; Enrica Morra; Gerassimos A Pangalis; Jesus F San Miguel; Andrew R Branagan; et al.
    Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
    Seminars in oncology 2003;30(2):110-5.
  • 2003: M Consuelo Del Cañizo; M Eugenia Fernández; Antonio López; Belén Vidriales; Eva Villarón; José L Arroyo; Francisco Ortuño; Alberto Orfao; Jesus F San Miguel
    Immunophenotypic analysis of myelodysplastic syndromes.
    Haematologica 2003;88(4):402-7.
  • 2003: José A Pérez-Simón; Rodrigo Martino; Adrián Alegre; José F Tomás; Angel De Leon; Dolores Caballero; Ana Sureda; Jordi Sierra; Jesús F San Miguel
    Chronic but not acute graft-versus-host disease improves outcome in multiple myeloma patients after non-myeloablative allogeneic transplantation.
    British journal of haematology 2003;121(1):104-8.
  • 2003: D Valcárcel; R Martino; D Caballero; M V Mateos; J A Pérez-Simón; C Canals; F Fernández; J Bargay; E Muñiz-Díaz; M Gonzalez; et al.
    Chimerism analysis following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning.
    Bone marrow transplantation 2003;31(5):387-92.
  • 2003: Ana Rasillo; María Dolores Tabernero; María Luz Sánchez; Martín Pérez de Andrés; Marta Martín Ayuso; José Hernández; María Jesús Moro; Javier Fernández-Calvo; José María Sayagués; Aglae Bortoluci; et al.
    Fluorescence in situ hybridization analysis of aneuploidization patterns in monoclonal gammopathy of undetermined significance versus multiple myeloma and plasma cell leukemia.
    Cancer 2003;97(3):601-9.
  • 2003: Norma C Gutiérrez; Jordi Camps; Jesús M Hernández; Juan L García; Esther Prat; M Belén González; Rosa Miró; Jesús F San Miguel
    Multicolor fluorescence in situ hybridization studies in multiple myeloma and monoclonal gammopathy of undetermined significance.
    The hematology journal : the official journal of the European Haematology Association / EHA 2003;4(1):67-70.
  • 2003: M D Caballero; J A Pérez-Simón; A Iriondo; J J Lahuerta; J Sierra; J Marín; M Gandarillas; R Arranz; J Zuazu; V Rubio; et al.
    High-dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group.
    Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(1):140-51.
  • 2002: J R González-Porras; M González; R García-Sanz; J F San Miguel
    Thalidomide in combination with cyclophosphamide and dexamethasone (thacydex) is effective in soft-tissue plasmacytomas.
    British journal of haematology 2002;119(3):883-4.
  • 2002: José A Pérez-Simón; Panagiotis D Kottaridis; Rodrigo Martino; Charles Craddock; Dolores Caballero; Raj Chopra; Javier García-Conde; Don W Milligan; Stephen Schey; Alvaro Urbano-Ispizua; et al.
    Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders.
    Blood 2002;100(9):3121-7.
  • 2002: Pablo Menéndez; Jose A Pérez-Simón; Maria V Mateos; Maria D Caballero; Marcos González; Jesus F San-Miguel; Alberto Orfao
    Influence of the different CD34+ and CD34- cell subsets infused on clinical outcome after non-myeloablative allogeneic peripheral blood transplantation from human leucocyte antigen-identical sibling donors.
    British journal of haematology 2002;119(1):135-43.
  • 2002: Pablo Menéndez; Maria D Caballero; Felipe Prosper; Maria C Del Cañizo; Jose A Pérez-Simón; Maria V Mateos; Maria J Nieto; Mercedes Corral; Mercedes Romero; Javier García-Conde; et al.
    The composition of leukapheresis products impacts on the hematopoietic recovery after autologous transplantation independently of the mobilization regimen.
    Transfusion 2002;42(9):1159-72.
  • 2002: Maria V Mateos; Ramón García-Sanz; Ricardo López-Pérez; Maria J Moro; Enrique Ocio; Jose Hernández; Marta Megido; Maria D Caballero; Javier Fernández-Calvo; Abelardo Bárez; et al.
    Methylation is an inactivating mechanism of the p16 gene in multiple myeloma associated with high plasma cell proliferation and short survival.
    British journal of haematology 2002;118(4):1034-40.
  • 2002: Rodrigo Martino; Granada Perea; María Dolores Caballero; María V Mateos; Josep M Ribera; Jaime Pérez de Oteyza; Reyes Arranz; María José Terol; Jorge Sierra; Jesús F San Miguel
    Cyclophosphamide, pegylated liposomal doxorubicin (Caelyx), vincristine and prednisone (CCOP) in elderly patients with diffuse large B-cell lymphoma: results from a prospective phase II study.
    Haematologica 2002;87(8):822-7.
  • 2002: M L Sánchez; J Almeida; B Vidriales; M C López-Berges; M A García-Marcos; M J Moro; A Corrales; M J Calmuntia; J F San Miguel; A Orfao
    Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation.
    Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2002;16(8):1460-9.
  • 2002: J A Pérez-Simón; D Caballero; M Diez-Campelo; R Lopez-Pérez; G Mateos; C Cañizo; L Vazquez; B Vidriales; M V Mateos; M Gonzalez; et al.
    Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation.
    Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2002;16(8):1423-31.
  • 2002: Alejandro Martín; Ramón García-Sanz; José Hernández; Joan Bladé; Begoña Suquía; Javier Fernández-Calvo; Marcos González; Gema Mateo; Alberto Orfao; Jesus F San Miguel
    Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant anti-tumour effect.
    British journal of haematology 2002;118(1):239-42.
  • 2002: Maria I González-Fraile; Ramoń García-Sanz; Maria V Mateos; Ana Balanzategui; Marcos González; Lourdes Váquez; Jesús F San Miguel
    Methylenetetrahydrofolate reductase genotype does not play a role in multiple myeloma pathogenesis.
    British journal of haematology 2002;117(4):890-2.
  • 2002: Jesús F San-Miguel; María B Vidriales; Alberto Orfão
    Immunological evaluation of minimal residual disease (MRD) in acute myeloid leukaemia (AML).
    Best practice & research. Clinical haematology 2002;15(1):105-18.
  • 2002: Jesús F San Miguel; Julia Almeida; Gema Mateo; Joan Bladé; Consuelo López-Berges; Dolores Caballero; José Hernández; María Jesús Moro; Javier Fernández-Calvo; Joaquín Díaz-Mediavilla; et al.
    Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome.
    Blood 2002;99(5):1853-6.
  • 2002: Josep-Maria Ribera; Juan-José Ortega; Albert Oriol; Isabel Granada; Jesús-Maria Hernández-Rivas; Ricardo Parody; Concepción Bethencourt; Concepción Rivas; Pilar Bastida; Eloy del Potro; et al.
    Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial.
    Haematologica 2002;87(2):154-66.
  • 2002: Ramón García-Sanz; Maria Isabel González-Fraile; Magdalena Sierra; Carlos López; Marcos González; Jesús Fernando San Miguel
    The combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is feasible and can be an option for relapsed/refractory multiple myeloma.
    The hematology journal : the official journal of the European Haematology Association / EHA 2002;3(1):43-8.
  • 2001: M González; R López-Pérez; R García-Sanz; J A Pérez-Simón; J F San Miguel
    Debate round-table: comments concerning chimerism studies.
    Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2001;15(12):1986-8.
  • 2001: L Suárez; B Vidriales; J García-Laraña; A López; R Martínez; V Martín-Reina; M Tormo; J D González-San Miguel; E Lavilla; R García-Boyero; et al.
    Multiparametric analysis of apoptotic and multi-drug resistance phenotypes according to the blast cell maturation stage in elderly patients with acute myeloid leukemia.
    Haematologica 2001;86(12):1287-95.
  • 2001: M Lima; J Almeida; A H Santos; M dos Anjos Teixeira; M C Alguero; M L Queirós; A Balanzategui; B Justiça; M Gonzalez; J F San Miguel; et al.
    Immunophenotypic analysis of the TCR-Vbeta repertoire in 98 persistent expansions of CD3(+)/TCR-alphabeta(+) large granular lymphocytes: utility in assessing clonality and insights into the pathogenesis of the disease.
    The American journal of pathology 2001;159(5):1861-8.
  • 2001: R López-Pérez; R García-Sanz; D González; A Balanzategui; M C Chillón; I Alaejos; M V Mateos; M D Caballero; M Corral; A Orfão; et al.
    Gene scanning of VDJH-amplified segments is a clinically relevant technique to detect contaminating tumor cells in the apheresis products of multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation.
    Bone marrow transplantation 2001;28(7):665-72.
  • 2001: J L Arroyo; M A García-Marcos; A López; P Menéndez; M D Tabernero; L I Sánchez-Abarca; C Avila-Zarza; J F San Miguel; A Orfao
    Evaluation of a CD61 MoAb method for enumeration of platelets in thrombocytopenic patients and its impact on the transfusion decision-making process.
    Transfusion 2001;41(10):1212-6.
  • 2001: J F San Miguel; M B Vidriales; C López-Berges; J Díaz-Mediavilla; N Gutiérrez; C Cañizo; F Ramos; M J Calmuntia; J J Pérez; M González; et al.
    Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification.
    Blood 2001;98(6):1746-51.
  • 2001: P Lucio; G Gaipa; E G van Lochem; E R van Wering; A Porwit-MacDonald; T Faria; E Bjorklund; A Biondi; M W van den Beemd; E Baars; et al.
    BIOMED-I concerted action report: flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings. BIOMED-1 Concerted Action Investigation of Minimal Residual Disease in Acute Leukemia: International Standardization and Clinical Evaluation.
    Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2001;15(8):1185-92.
  • 2001: J J Ortega; J M Ribera; A Oriol; P Bastida; M E González; C Calvo; I Egurbide; J M Hernández Rivas; C Rivas; A Alcalá; et al.
    Early and delayed consolidation chemotherapy significantly improves the outcome of children with intermediate risk acute lymphoblastic leukemia. Final results of the prospective randomized PETHEMA ALL-89 TRIAL.
    Haematologica 2001;86(6):586-95.
  • 2001: M A Canales; M C Fernández-Jiménez; A Martín; R Arrieta; M D Caballero; J Díez; E Quevedo; J García-Bustos; J F San Miguel; F Hernández-Navarro
    Identification of factors associated with poor peripheral blood progenitor cell mobilization in Hodgkin's disease.
    Haematologica 2001;86(5):494-8.
  • 2001: N C Gutiérrez; J M Hernández; J L García; M C Cañizo; M González; J Hernández; M B González; M A Garciá-Marcos; J F San Miguel
    Differences in genetic changes between multiple myeloma and plasma cell leukemia demonstrated by comparative genomic hybridization.
    Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2001;15(5):840-5.
  • 2001: J M Hernández; J L García; N C Gutiérrez; M Mollejo; J A Martínez-Climent; T Flores; M B González; M A Piris; J F San Miguel
    Novel genomic imbalances in B-cell splenic marginal zone lymphomas revealed by comparative genomic hybridization and cytogenetics.
    The American journal of pathology 2001;158(5):1843-50.
  • 2001: A Martín; M C Fernández-Jiménez; M D Caballero; M A Canales; J A Pérez-Simón; J García de Bustos; L Vázquez; F Hernández-Navarro; J F San Miguel
    Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease.
    British journal of haematology 2001;113(1):161-71.
  • 2001: M I González-Fraile; C Cañizo; D Caballero; R Hernández; L Vázquez; C López; A Izarra; J L Arroyo; A de la Loma; M J Otero; et al.
    Cidofovir treatment of human polyomavirus-associated acute haemorrhagic cystitis.
    Transplant infectious disease : an official journal of the Transplantation Society 2001;3(1):44-6.
  • 2001: P Menéndez; F Prósper; C Bueno; C Arbona; J F San Miguel; J García-Conde; C Solá; J Hornedo; H Cortés-Funes; A Orfao
    Sequential analysis of CD34+ and CD34- cell subsets in peripheral blood and leukapheresis products from breast cancer patients mobilized with SCF plus G-CSF and cyclophosphamide.
    Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2001;15(3):430-9.
  • 2001: M D Tabernero; A M Bortoluci; I Alaejos; M C López-Berges; A Rasillo; R García-Sanz; M García; J M Sayagués; M González; G Mateo; et al.
    Adult precursor B-ALL with BCR/ABL gene rearrangements displays a unique immunophenotype based on the pattern of CD10, CD34, CD13 and CD38 expresssion.
    Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2001;15(3):406-14.
  • 2001: C Bueno; J Almeida; M C Alguero; M L Sánchez; J M Vaquero; F J Laso; J F San Miguel; L Escribano; A Orfao
    Flow cytometric analysis of cytokine production by normal human peripheral blood dendritic cells and monocytes: comparative analysis of different stimuli, secretion-blocking agents and incubation periods.
    Cytometry 2001;46(1):33-40.
  • 2001: C M Chillón; R García-Sanz; A Balanzategui; F Ramos; J Fernández-Calvo; M J Rodríguez; M I Rodríguez-Salazar; A Corrales; M J Calmuntia; A Orfão; et al.
    Molecular characterization of acute myeloblastic leukemia according to the new WHO classification: a different distribution in Central-West Spain.
    Haematologica 2001;86(2):162-6.
  • 2001: J Bladé; J F San Miguel; M Fontanillas; J Esteve; J Maldonado; A Alcalá; S Brunet; J García-Conde; J Besalduch; M J Moro; et al.
    Increased conventional chemotherapy does not improve survival in multiple myeloma: long-term results of two PETHEMA trials including 914 patients.
    The hematology journal : the official journal of the European Haematology Association / EHA 2001;2(4):272-8.
  • 2001: M V Mateos; R Garcia-Sanz; R López-Pérez; A Balanzategui; M I González; J Fernández-Calvo; M J Moro; J Hernández; M D Caballero; M González; et al.
    p16/INK4a gene inactivation by hypermethylation is associated with aggressive variants of monoclonal gammopathies.
    The hematology journal : the official journal of the European Haematology Association / EHA 2001;2(3):146-9.
  • 2000: J L Arroyo; N C Gutierrez; M A García-Marcos; R Villarroel; P Galindo; M E Fernández; A Izarra; M C del Cañizo ; M D Caballero; J F San Miguel
    Monocyte counts: an early index of haemopoietic reconstitution after peripheral blood stem cell transplantation.
    British journal of haematology 2000;111(3):987-9.
  • 2000: R Hernández; M C del Cañizo; C López; M I González; M L Vázquez; M D Caballero; J F San Miguel
    Pathologic rupture of the spleen during induction with ATRA in a patient with acute promyelocytic leukemia.
    Medical oncology (Northwood, London, England) 2000;17(4):337-9.
  • 2000: N C Gutiérrez; J M Hernández; J L García; J Almeida; G Mateo; M I González; J Hernández; J Fernández-Calvo; J F San Miguel
    Correlation between cytogenetic abnormalities and disease characteristics in multiple myeloma: monosomy of chromosome 13 and structural abnormalities of 11q are associated with a high percentage of S-phase plasma cells.
    Haematologica 2000;85(11):1146-52.
  • 2000: M I González; D Caballero; C López; T Alburquerque; R Hernández; A de la Loma; C Cañizo; L Vázquez; J F San Miguel
    Cerebral toxoplasmosis and Guillain-Barré syndrome after allogeneic peripheral stem cell transplantation.
    Transplant infectious disease : an official journal of the Transplantation Society 2000;2(3):145-9.
  • 2000: R López-Pérez; R García-Sanz; D González; A Balanzategui; M C Chillón; I Alaejos; M V Mateos; M D Caballero; G Mateo; M J Nieto; et al.
    The detection of contaminating clonal cells in apheresis products is related to response and outcome in multiple myeloma undergoing autologous peripheral blood stem cell transplantation.
    Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2000;14(8):1493-9.
  • 2000: M V Mateos; M González; A Balanzategui; R López-Pérez; D González; M C Chillón; I Alaejos; R García-Sanz; J F San Miguel
    Status of methylation of p16 gene in multiple myeloma: a comparative study of three methods for its detection.
    Clinical biochemistry 2000;33(5):415-8.
  • 2000: M I González; D Caballero; L Vázquez; C Cañizo; R Hernández; C López; A Izarra; J L Arroyo; M González; R García; et al.
    Allogeneic peripheral stem cell transplantation in a case of hereditary sideroblastic anaemia.
    British journal of haematology 2000;109(3):658-60.
  • 2000: A Porwit-MacDonald; E Björklund; P Lucio; E G van Lochem; J Mazur; A Parreira; M W van den Beemd; E R van Wering; E Baars; G Gaipa; et al.
    BIOMED-1 concerted action report: flow cytometric characterization of CD7+ cell subsets in normal bone marrow as a basis for the diagnosis and follow-up of T cell acute lymphoblastic leukemia (T-ALL).
    Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2000;14(5):816-25.
  • 2000: J M Hernández; M C del Cañizo; A Cuneo; J L García; N C Gutiérrez; M González; G Castoldi; J F San Miguel
    Clinical, hematological and cytogenetic characteristics of atypical chronic myeloid leukemia.
    Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(4):441-4.
  • 2000: L Vazquez; D Caballero; C D Cañizo; C Lopez; R Hernandez; I Gonzalez; T Flores; J F San Miguel
    Allogeneic peripheral blood cell transplantation for hypereosinophilic syndrome with myelofibrosis.
    Bone marrow transplantation 2000;25(2):217-8.
  • 2000: M González; M V Mateos; R García-Sanz; A Balanzategui; R López-Pérez; M C Chillón; D González; I Alaejos; J F San Miguel
    De novo methylation of tumor suppressor gene p16/INK4a is a frequent finding in multiple myeloma patients at diagnosis.
    Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2000;14(1):183-7.
  • 2000: J M Hernández; M B González; J L García; M T Ferro; N C Gutiérrez; P Marynen; J F San Miguel
    Two cases of myeloid disorders and a t(8;12) (q12;p13).
    Haematologica 2000;85(1):31-4.
  • 1999: J F San Miguel; J Ciudad; M B Vidriales; A Orfao; P Lucio; A Porwit-MacDonald; G Gaipa; E van Wering; J J van Dongen
    Immunophenotypical detection of minimal residual disease in acute leukemia.
    Critical reviews in oncology/hematology 1999;32(3):175-85.
  • 1999: J A Pérez-Simón; A Martín; D Caballero; M Corral; M J Nieto; M Gonzalez; L Vazquez; C López-Berges; M C Cañizo; M V Mateos; et al.
    Clinical significance of CD34+ cell dose in long-term engraftment following autologous peripheral blood stem cell transplantation.
    Bone marrow transplantation 1999;24(12):1279-83.
  • 1999: C del Cañizo; J Galende; J Almeida; A Brufau; A Mota; J F San Miguel
    In vitro growth in acute myeloblastic leukemia: clinico-biological correlations.
    Leukemia & lymphoma 1999;36(1-2):1-7.
  • 1999: J Almeida; C Bueno; M C Alguero; M L Sanchez; M C Cañizo; M E Fernandez; J M Vaquero; F J Laso; L Escribano; J F San Miguel; et al.
    Extensive characterization of the immunophenotype and pattern of cytokine production by distinct subpopulations of normal human peripheral blood MHC II+/lineage- cells.
    Clinical and experimental immunology 1999;118(3):392-401.
  • 1999: R García-Sanz; I Alaejos; A Orfão; A Rasillo; M C Chillón; M D Tabernero; M V Mateos; R López-Pérez; D González; A Balanzategui; et al.
    Low frequency of the TEL/AML1 fusion gene in acute lymphoblastic leukaemia in Spain.
    British journal of haematology 1999;107(3):667-9.
  • 1999: J Almeida; A Orfao; M Ocqueteau; G Mateo; M Corral; M D Caballero; J Blade; M J Moro; J Hernandez; J F San Miguel
    High-sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in multiple myeloma.
    British journal of haematology 1999;107(1):121-31.
  • 1999: A Orfao; G Schmitz; B Brando; A Ruiz-Arguelles; G Basso; R Braylan; G Rothe; F Lacombe; F Lanza; S Papa; et al.
    Clinically useful information provided by the flow cytometric immunophenotyping of hematological malignancies: current status and future directions.
    Clinical chemistry 1999;45(10):1708-17.
  • 1999: M González; D González; R López-Pérez; R García-Sanz; M C Chillón; A Balanzategui; M V Mateos; I Alaejos; A W Langerak; A Orfão; et al.
    Heteroduplex analysis of VDJ amplified segments from rearranged IgH genes for clonality assessments in B-cell non-Hodgkin's lymphoma. A comparison between different strategies.
    Haematologica 1999;84(9):779-84.
  • 1999: J L García; N C Gutiérrez; J M Hernández; M A Sánchez; M B González; J L Arroyo; J F San Miguel
    [Comparative genomic hybridization. Methodologic features].
    Sangre 1999;44(4):291-6.
  • 1999: B Díaz-Agustín; L Escribano; P Bravo; S Herrero; R Nuñez; R Navalón; L Navarro; A Torrelo; A Cantalapiedra; L Del Castillo; et al.
    The CD69 early activation molecule is overexpressed in human bone marrow mast cells from adults with indolent systemic mast cell disease.
    British journal of haematology 1999;106(2):400-5.
  • 1999: M L Amigo; M C del Cañizo; M D Caballero; L Vazquez; M Corral; B Vidriales; A Brufau; J F San Miguel
    Factors that influence long-term hematopoietic function following autologous stem cell transplantation.
    Bone marrow transplantation 1999;24(3):289-93.
  • 1999: M L Amigo; M C del Cañizo; A Rios; M A Garcia; M D Caballero; A Martin; N Bermejo; P Vilches; J F San Miguel
    Diagnosis of secondary myelodysplastic syndromes (MDS) following autologous transplantation should not be based only on morphological criteria used for diagnosis of de novo MDS.
    Bone marrow transplantation 1999;23(10):997-1002.
  • 1999: C del Cañizo; N Lopez; D Caballero; E Fernandez; A Brufau; L Vazquez; V Mateos; N Gutierrez; J F San Miguel
    Haematopoietic damage persists 1 year after autologous peripheral blood stem cell transplantation.
    Bone marrow transplantation 1999;23(9):901-5.
  • 1999: A Orfao; M C Chillón; A M Bortoluci; M C López-Berges; R García-Sanz; M Gonzalez; M D Tabernero; M A García-Marcos; A I Rasillo; J Hernández-Rivas; et al.
    The flow cytometric pattern of CD34, CD15 and CD13 expression in acute myeloblastic leukemia is highly characteristic of the presence of PML-RARalpha gene rearrangements.
    Haematologica 1999;84(5):405-12.
  • 1999: A Martínez; J F San Miguel; M B Vidriales; J Ciudad; M D Caballero; M C López-Berges; M J Moro; M J Calmuntia; F Ortega; A Orfao
    An abnormal CD34+ myeloid/CD34+ lymphoid ratio at the end of chemotherapy predicts relapse in patients with acute myeloid leukemia.
    Cytometry 1999;38(2):70-5.
  • 1999: R García-Sanz; R López-Pérez; A W Langerak; D González; M C Chillón; A Balanzategui; M V Mateos; I Alaejos; M González; J J Van Dongen; et al.
    Heteroduplex PCR analysis of rearranged immunoglobulin genes for clonality assessment in multiple myeloma.
    Haematologica 1999;84(4):328-35.
  • 1999: J Ciudad; J F San Miguel; M C López-Berges; M A García Marcos; M González; L Vázquez; M C del Cañizo; A López; J J Van Dongen; A Orfao
    Detection of abnormalities in B-cell differentiation pattern is a useful tool to predict relapse in precursor-B-ALL.
    British journal of haematology 1999;104(4):695-705.
  • 1999: P Lúcio; A Parreira; M W van den Beemd; E G van Lochem; E R van Wering; E Baars; A Porwit-MacDonald; E Bjorklund; G Gaipa; A Biondi; et al.
    Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL.
    Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1999;13(3):419-27.
  • 1999: C Cerveró; L Escribano; J F San Miguel; B Díaz-Agustín; P Bravo; J Villarrubia; R García-Sanz; J L Velasco; P Herrera; M Vargas; et al.
    Expression of Bcl-2 by human bone marrow mast cells and its overexpression in mast cell leukemia.
    American journal of hematology 1999;60(3):191-5.
  • 1999: J A Pérez-Simón; B Valverde; A Martínez; D Tabernero; J Almeida; N Gutierrez; J F San Miguel; A Orfao
    Correlation of rhodamine 123 efflux by neoplastic plasma cells with clinical and biological characteristics of multiple myeloma.
    Cytometry 1999;38(1):24-9.
  • 1999: J Almeida; A Orfao; G Mateo; M Ocqueteau; R García-Sanz; M J Moro; J Hernandez; F Ortega; D Borrego; A Barez; et al.
    Immunophenotypic and DNA content characteristics of plasma cells in multiple myeloma and monoclonal gammopathy of undetermined significance.
    Pathologie-biologie 1999;47(2):119-27.
  • 1999: J F San Miguel; J Bladé Creixenti; R García-Sanz
    Treatment of multiple myeloma.
    Haematologica 1999;84(1):36-58.
  • 1998: P Menéndez; O Redondo; A Rodriguez; M C Lopez-Berges; G Ercilla; A López; A Durán; J Almeida; J A Pérez-Simón; J F San Miguel; et al.
    Comparison between a lyse-and-then-wash method and a lyse-non-wash technique for the enumeration of CD34+ hematopoietic progenitor cells.
    Cytometry 1998;34(6):264-71.
  • 1998: J Ciudad; A Orfao; B Vidriales; A Macedo; A Martínez; M González; M C López-Berges; B Valverde; J F San Miguel
    Immunophenotypic analysis of CD19+ precursors in normal human adult bone marrow: implications for minimal residual disease detection.
    Haematologica 1998;83(12):1069-75.
  • 1998: J Ciudad; J F San Miguel; M C López-Berges; B Vidriales; B Valverde; M Ocqueteau; G Mateos; M D Caballero; J Hernández; M J Moro; et al.
    Prognostic value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(12):3774-81.
  • 1998: L Escribano; A Orfao; B Díaz Agustín; C Cerveró; S Herrero; J Villarrubia; P Bravo; A Torrelo; T Montero; M Valdemoro; et al.
    Human bone marrow mast cells from indolent systemic mast cell disease constitutively express increased amounts of the CD63 protein on their surface.
    Cytometry 1998;34(5):223-8.
  • 1998: J M Hernández; N C Gutiérrez; J Almeida; J L García; M A Sánchez; G Mateo; A Ríos; J F San Miguel
    IL-4 improves the detection of cytogenetic abnormalities in multiple myeloma and increases the proportion of clonally abnormal metaphases.
    British journal of haematology 1998;103(1):163-7.
  • 1998: M C del Cañizo; A Brufau; J Almeida; J Galende; M A García Marcos; A Mota; R García; J Fernández Calvo; F Ramos; P Fisac; et al.
    In vitro growth in acute myeloblastic leukaemia: relationship with other clinico-biological characteristics of the disease.
    British journal of haematology 1998;103(1):137-42.
  • 1998: M L Amigo; M C del Cañizo; J M Hernández; M B Gonzalez; N Gutiérrez; M V Mateos; J F San Miguel
    Clonal myelodysplastic cells present in apheresis product before transplantation.
    Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1998;12(9):1497-9.
  • 1998: J F San Miguel; R García-Sanz
    Recombinant human erythropoietin in the anaemia of multiple myeloma and non-Hodgkin's lymphoma.
    Medical oncology (Northwood, London, England) 1998;15 Suppl 1():S29-34.
  • 1998: L Escribano; M Ocqueteau; J Almeida; A Orfao; J F San Miguel
    Expression of the c-kit (CD117) molecule in normal and malignant hematopoiesis.
    Leukemia & lymphoma 1998;30(5-6):459-66.
  • 1998: J Bladé; J F San Miguel; M L Escudero; M Fontanillas; J Besalduch; S Gardella; J Arias; J García-Conde; M Carnero; J M Marti; et al.
    Maintenance treatment with interferon alpha-2b in multiple myeloma: a prospective randomized study from PETHEMA (Program for the Study and Treatment of Hematological Malignancies, Spanish Society of Hematology).
    Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1998;12(7):1144-8.
  • 1998: M D Hernández; M C del Cañizo; M González; M D Caballero; M C López-Berges; L Vázquez; A Orfao; M Corral; M J Nieto; J F San Miguel
    [Immune reconstitution after autologous progenitor hemopoietic cell transplantation. A study comparing autologous bone marrow and autologous peripheral blood transplantation].
    Medicina clínica 1998;110(20):768-73.
  • 1998: M D Caballero; L Vazquez; J M Barragan; J J Cruz; A Gomez; M J Nieto; M Corral; E Fonseca; J F San Miguel
    Randomized study of filgrastim versus molgramostim after peripheral stem cell transplant in breast cancer.
    Haematologica 1998;83(6):514-8.
  • 1998: M Ocqueteau; A Orfao; J Almeida; J Bladé; M González; R García-Sanz; C López-Berges; M J Moro; J Hernández; L Escribano; et al.
    Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma.
    The American journal of pathology 1998;152(6):1655-65.
  • 1998: F J Laso; M C Iglesias; A López; J Ciudad; J F San Miguel; A Orfao
    Increased interleukin-12 serum levels in chronic alcoholism.
    Journal of hepatology 1998;28(5):771-7.
  • 1998: J A Pérez-Simón; R García-Sanz; M D Tabernero; J Almeida; M González; J Fernández-Calvo; M J Moro; J M Hernández; J F San Miguel; A Orfão
    Prognostic value of numerical chromosome aberrations in multiple myeloma: A FISH analysis of 15 different chromosomes.
    Blood 1998;91(9):3366-71.
  • 1998: J A Pérez-Simón; M D Caballero; M Corral; M J Nieto; A Orfao; L Vazquez; M L Amigo; C Berges; M González; C Del Cañizo; et al.
    Minimal number of circulating CD34+ cells to ensure successful leukapheresis and engraftment in autologous peripheral blood progenitor cell transplantation.
    Transfusion 1998;38(4):385-91.
  • 1998: J M Ribera; J J Ortega; A Oriol; M Fontanillas; J M Hernández-Rivas; S Brunet; J García-Conde; J Maldonado; J Zuazu; S Gardella; et al.
    Late intensification chemotherapy has not improved the results of intensive chemotherapy in adult acute lymphoblastic leukemia. Results of a prospective multicenter randomized trial (PETHEMA ALL-89). Spanish Society of Hematology.
    Haematologica 1998;83(3):222-30.
  • 1998: R García-Sanz; M Vargas Montero; M Gonzalez Díaz; M del Carmen; C Santos; A Balanzategui Echevarria; T Flores Corral; J M Hernández Martín; M D Caballero Barrigón; J F San Miguel
    Detection of single and associated lesions of the Bcl-1, Bcl-2, Bcl-6, c-myc, p53 and p16 genes in B-cell non-Hodgkin's lymphomas: value of molecular analysis for a better assignment of the histologic subtype.
    Haematologica 1998;83(3):209-16.
  • 1998: L Escribano; A Orfao; J Villarrubia; B Díaz-Agustín; C Cerveró; A Rios; J L Velasco; J Ciudad; J L Navarro; J F San Miguel
    Immunophenotypic characterization of human bone marrow mast cells. A flow cytometric study of normal and pathological bone marrow samples.
    Analytical cellular pathology : the journal of the European Society for Analytical Cellular Pathology 1998;16(3):151-9.
  • 1998: M C Del Cañizo; A Brufau; A Mota; N Lopez; M E Fernandez; C Vallejo; J M Hernandez; J L Garcia; J F San Miguel
    The value of cell cultures for the diagnosis of mixed myelodysplastic/myeloproliferative disorders.
    Haematologica 1998;83(1):3-7.
  • 1997: R García-Sanz; M González; M Vargas; M C Chillón; A Balanzategui; M Barbón; M T Flores; J F San Miguel
    Deletions and rearrangements of cyclin-dependent kinase 4 inhibitor gene p16 are associated with poor prognosis in B cell non-Hodgkin's lymphomas.
    Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1997;11(11):1915-20.
  • 1997: C Vallejo; M D Caballero; R García-Sanz; J M Hernández; L Vázquez; M C Cañizo; J Galende; C I Colino; A Gil-Hurlé; J F San Miguel
    Sequential intravenous-oral ciprofloxacin plus amoxycillin/clavulanic acid shortens hospital stay in infected non severe neutropenic patients.
    Hematology and cell therapy 1997;39(5):223-7.
  • 1997: F J Laso; P Lapeña; J I Madruga; J F San Miguel; A Orfao; M C Iglesias; M Alvarez-Mon
    Alterations in tumor necrosis factor-alpha, interferon-gamma, and interleukin-6 production by natural killer cell-enriched peripheral blood mononuclear cells in chronic alcoholism: relationship with liver disease and ethanol intake.
    Alcoholism, clinical and experimental research 1997;21(7):1226-31.
  • 1997: C Vallejo; M A García-Marcos; M C Del Cañizo; A Orfao; J Almeida; L Escribano; J F San Miguel; A Ríos
    [Syndrome of abnormal chromatin clumping in leucocytes with a high fraction of bone marrow cells in S-phase and in vitro autonomous growth].
    Medicina clínica 1997;109(9):340-2.
  • 1997: J F San Miguel; A Martínez; A Macedo; M B Vidriales; C López-Berges; M González; D Caballero; M A García-Marcos; F Ramos; J Fernández-Calvo; et al.
    Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients.
    Blood 1997;90(6):2465-70.
  • 1997: M L Amigo; M D Caballero; L Vazquez; T Flores; A López; J F San Miguel
    Immune thrombocytopenic purpura secondary to endometriosis.
    Haematologica 1997;82(5):602-3.
  • 1997: M García-Isidoro; M D Tabernero; M L Najera; J L García; J M Hernandez; A Duran; J F San Miguel; A Orfao
    Clinical and biological characteristics of myelodysplastic syndromes with nulisomy Y by fish.
    Haematologica 1997;82(5):537-41.
  • 1997: A Martínez; J F San Miguel; B Valverde; A Bárez; M J Moro; M A García-Marcos; J A Pérez-Simón; B Vidriales; A Orfao
    Functional expression of MDR-1 in acute myeloid leukemia: correlation with the clinical-biological, immunophenotypical, and prognostic disease characteristics.
    Annals of hematology 1997;75(3):81-6.
  • 1997: M D Caballero; V Rubio; J Rifon; I Heras; R García-Sanz; L Vázquez; B Vidriales; M C del Cañizo; M Corral; M Gonzalez; et al.
    BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors.
    Bone marrow transplantation 1997;20(6):451-8.
  • 1997: M C Del Cañizo; J Galende; A Mota; A Orfao; A Martinez; J Almeida; J F San Miguel
    In leukemic hematopoiesis CD34 antigen does not have the same significance as it does normal hematopoiesis.
    Leukemia research 1997;21(7):651-6.
  • 1997: M Garcia-Isidoro; M D Tabernero; M L Najera; M C Lopez-Berges; A Martinez; A Durán; J L Garcia; J M Hernandez; M A Garcia Marcos; J F San Miguel; et al.
    Association between trisomy 8 and the immunophenotype of blast cells from acute leukemias secondary to a myelodysplastic syndrome or chronic myeloproliferative disorders.
    Annals of hematology 1997;74(5):209-14.
  • 1997: F J Laso; J I Madruga; J A Girón; A López; J Ciudad; J F San Miguel; M Alvarez-Mon; A Orfao
    Decreased natural killer cytotoxic activity in chronic alcoholism is associated with alcohol liver disease but not active ethanol consumption.
    Hepatology (Baltimore, Md.) 1997;25(5):1096-100.
  • 1997: L Escribano; A Orfao; J Villarrubia; F Martín; J I Madruga; M Cuevas; J L Velasco; A Rios; J F San Miguel
    Sequential immunophenotypic analysis of mast cells in a case of systemic mast cell disease evolving to a mast cell leukemia.
    Cytometry 1997;30(2):98-102.
  • 1997: D Caballero; V Rubio; J Rifon; I Heras; R García-Sanz; B Vidriales; J A Pérez-Simón; C del Cañizo; M González; A León; et al.
    [Autologous transplant with BEAM protocol in lymphoma].
    Sangre 1997;42 Suppl 1():46-9.
  • 1997: L López; J A Portero; D Borrego; A Barez; J F San Miguel
    [High cardiac output in myeloma patients. Its prevalence and clinical characteristics. The Castile-León Cooperative Group for the Study of Monoclonal Gammapathies].
    Medicina clínica 1997;108(6):214-6.
  • 1997: M D Caballero; M L Amigo; J M Hernández; L Vazquez; C del Cañizo; M Gonzalez; R García; J F San Miguel
    Alternating mini-BEAM/ESHAP as salvage therapy for refractory non-Hodgkin's lymphomas.
    Annals of hematology 1997;74(2):79-82.
  • 1997: C Sanfructuoso; M D Caballero; L Vázquez; J Galende; J Almeida; J F San Miguel
    Rhabdomyolysis associated with septicemia after autologous bone marrow transplantation.
    Bone marrow transplantation 1997;19(1):95.
  • 1996: F J Laso; J I Madruga; J F San Miguel; J Ciudad; A López; M Alvarez Mon; A Orfao
    Long lasting immunological effects of ethanol after withdrawal.
    Cytometry 1996;26(4):275-80.
  • 1996: F Dolbeare; N Lopez; A Lopez; M L Amigo; J Ciudad; M C Del Cañizo; J F San Miguel; A Orfao
    Multiparametric cell-cycle analysis of peripheral blood-activated lymphocyte subsets using staining based on the TdT method for incorporated BrdUrd.
    Cytometry 1996;25(4):317-23.
  • 1996: M Ocqueteau; A Orfao; R García-Sanz; J Almeida; M Gonzalez; J F San Miguel
    Expression of the CD117 antigen (c-Kit) on normal and myelomatous plasma cells.
    British journal of haematology 1996;95(3):489-93.
  • 1996: A Orfao; L Escribano; J Villarrubia; J L Velasco; C Cerveró; J Ciudad; J L Navarro; J F San Miguel
    Flow cytometric analysis of mast cells from normal and pathological human bone marrow samples: identification and enumeration.
    The American journal of pathology 1996;149(5):1493-9.
  • 1996: N López Holgado; M Consuelo del Cañizo; M D Tabernero; M D Hernández; C Vallejo; J F San Miguel
    [Long-term culture: evidence of the capacity of stroma to sustain hematopoiesis of a second inoculum].
    Sangre 1996;41(5):345-9.
  • 1996: J F San Miguel; R García-Sanz; M González; A Orfão
    DNA cell content studies in multiple myeloma.
    Leukemia & lymphoma 1996;23(1-2):33-41.
  • 1996: M Ocqueteau; J F San Miguel; M González; J Almeida; A Orfao
    Do myelomatous plasma cells really express surface immunoglobulins?
    Haematologica 1996;81(5):460-3.
  • 1996: M González; R García-Sanz; M Vargas; A Balanzategui; M C Chillón; M V Mateos; J F San Miguel
    [Molecular biology in malignant blood diseases. Clinical applications. Study of immunoglobulin and T-cell receptor genes and molecular analysis of the translocations].
    Sangre 1996;41(4):321-34.
  • 1996: M González; R García Sanz; M C Chillon; A Balanzategui; M Vargas; M F García; J F San Miguel
    [Molecular biology in malignant blood diseases. Methodological aspects: Southern blotting techniques and the polymerase chain reaction].
    Sangre 1996;41(4):311-9.
  • 1996: J F San Miguel; M D Hernández; M Gonzalez; M C López-Berges; M D Caballero; L Vazquez; A Orfao; M J Nieto; M Corral; M C del Cañizo
    A randomized study comparing the effect of GM-CSF and G-CSF on immune reconstitution after autologous bone marrow transplantation.
    British journal of haematology 1996;94(1):140-7.
  • 1996: D Tabernero; J F San Miguel; M Garcia-Sanz; L Nájera; M García-Isidoro; J A Peréz-Simon; M Gonzalez; J Wiegant; A K Raap; A Orfão
    Incidence of chromosome numerical changes in multiple myeloma: fluorescence in situ hybridization analysis using 15 chromosome-specific probes.
    The American journal of pathology 1996;149(1):153-61.
  • 1996: J Bladé; J F San Miguel; M Fontanillas; A Alcalá; J Maldonado; J García-Conde; E Conde; G Conzález-Brito; M J Moro; M L Escudero; et al.
    Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/ autotransplantation and who were conventionally treated.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(7):2167-73.
  • 1996: M C del Cañizo; A Mota; A Orfao; J Galende; M D Caballero; M A Garcia Marcos; J F San Miguel
    Value of colony forming unit-granulocyte macrophage assay in predicting relapse in acute myeloid leukaemia.
    Journal of clinical pathology 1996;49(6):450-2.
  • 1996: J Almeida; M Consuelo Del Cañizo; J Galende; J F San Miguel
    Responsiveness of AML cells to recombinant hematopoietic growth factors: relationship with morphological and immunological characteristics of blast cells.
    Leukemia research 1996;20(6):533-4.
  • 1996: J F San Miguel; G F Sanz; T Vallespí; M C del Cañizo; M A Sanz
    Myelodysplastic syndromes.
    Critical reviews in oncology/hematology 1996;23(1):57-93.
  • 1996: R García-Sanz; M González; A Orfão; M J Moro; J M Hernández; D Borrego; M Carnero; F Casanova; A Bárez; R Jiménez; et al.
    Analysis of natural killer-associated antigens in peripheral blood and bone marrow of multiple myeloma patients and prognostic implications.
    British journal of haematology 1996;93(1):81-8.
  • 1996: C Sanfructuoso; M D Caballero; R Garcia-Sanz; B Vidriales; L Vazquez; J F San Miguel
    Relapse of multiple myeloma in extramedullary sites after autologous bone marrow transplantation.
    European journal of haematology 1996;56(3):181-3.
  • 1996: A Macedo; J F San Miguel; M B Vidriales; M C López-Berges; M A García-Marcos; M Gonzalez; C Landolfi; A Orfão
    Phenotypic changes in acute myeloid leukaemia: implications in the detection of minimal residual disease.
    Journal of clinical pathology 1996;49(1):15-8.
  • 1995: M L Amigo; R Revilla; C Sánchez; C del Cañizo; D Caballero; J F San Miguel
    [Spinal cord compression as the presenting form of non-Hodgkin's lymphoma].
    Sangre 1995;40(6):505-7.
  • 1995: L Escribano; A Orfao; J Villarrubia; C Cerveró; J L Velasco; F Martín; J F San Miguel; J L Navarro
    Expression of lymphoid-associated antigens in mast cells: report of a case of systemic mast cell disease.
    British journal of haematology 1995;91(4):941-3.
  • 1995: A Macedo; A Orfao; J Ciudad; M Gonzalez; B Vidriales; M C Lopez-Berges; A Martínez; C Landolfi; C Cañizo; J F San Miguel
    Phenotypic analysis of CD34 subpopulations in normal human bone marrow and its application for the detection of minimal residual disease.
    Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1995;9(11):1896-901.
  • 1995: J Almeida; M A García-Marcos; C Vallejo; M T Flores; M D Caballero; J F San Miguel; A Ríos
    [Results of a series of 104 consecutive bilateral bone marrow biopsy specimens in lymphoproliferative disorders].
    Sangre 1995;40(5):365-8.
  • 1995: M D Tabernero; J F San Miguel; J L Garcia; M Garcia-Isidoro; J Wiegant; J Ciudad; M Gonzalez; A Rios; A Raap; A Orfao
    Clinical, biological, and immunophenotypical characteristics of B-cell chronic lymphocytic leukemia with trisomy 12 by fluorescence in situ hybridization.
    Cytometry 1995;22(3):217-22.
  • 1995: A Macedo; A Orfão; M Gonzalez; M B Vidriales; M C López-Berges; A Martínez; J F San Miguel
    Immunological detection of blast cell subpopulations in acute myeloblastic leukemia at diagnosis: implications for minimal residual disease studies.
    Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1995;9(6):993-8.
  • 1995: J Almeida; C del Cañizo; A Orfao; J Hernandez; D Hernandez; J Galende; D Caballero; R Garcia-Sanz; J F San Miguel
    In vitro autonomous proliferation in ANLL: clinical and biological significance.
    Leukemia research 1995;19(6):411-6.
  • 1995: M B Vidriales; A Orfao; M C López-Berges; M González; A López-Macedo; M A García; J Galende; J F San Miguel
    Light scatter characteristics of blast cells in acute myeloid leukaemia: association with morphology and immunophenotype.
    Journal of clinical pathology 1995;48(5):456-62.
  • 1995: M B Vidriales; A Orfao; M C López-Berges; M González; A López-Macedo; J Ciudad; A López; M C Cañizo; M A Garcia; J F San Miguel
    DNA aneuploidy in acute myeloblastic leukemia is associated with a high expression of lymphoid markers.
    Cytometry 1995;22(1):22-5.
  • 1995: C Iglesias-Osma; L Gonzalez-Villaron; J F San Miguel; M D Caballero; L Vazquez; S de Castro
    Iron metabolism and fungal infections in patients with haematological malignancies.
    Journal of clinical pathology 1995;48(3):223-5.
  • 1995: A Macedo; A Orfao; A Martínez; M B Vidriales; B Valverde; M C López-Berges; J F San Miguel
    Immunophenotype of c-kit cells in normal human bone marrow: implications for the detection of minimal residual disease in AML.
    British journal of haematology 1995;89(2):338-41.
  • 1995: J F San Miguel; R García-Sanz; M González; M J Moro; J M Hernández; F Ortega; D Borrego; M Carnero; F Casanova; R Jiménez
    A new staging system for multiple myeloma based on the number of S-phase plasma cells.
    Blood 1995;85(2):448-55.
  • 1995: A Orfao; J Ciudad; M Gonzalez; A Lopez; M del Mar Abad; J I Paz Bouza; J J Cruz; A Gomez Alonso; J F San Miguel
    Flow cytometry in the diagnosis of cancer.
    Scandinavian journal of clinical and laboratory investigation. Supplementum 1995;221():145-52.
  • 1995: I Sánchez; J F San Miguel; J Corral; C Martín; R Pérez; M González; M C Cañizo; A Orfao; R González-Sarmiento
    Gene rearrangement in acute non-lymphoblastic leukaemia: correlation with morphological and immunophenotypic characteristics of blast cells.
    British journal of haematology 1995;89(1):104-9.
  • 1994: A Orfäo; R García-Sanz; M C López-Berges; M Belén Vidriales; M González; M D Caballero; J F San Miguel
    A new method for the analysis of plasma cell DNA content in multiple myeloma samples using a CD38/propidium iodide double staining technique.
    Cytometry 1994;17(4):332-9.
  • 1994: J Galende; M L Vazquez; J Almeida; M C Peña Penabad; E Fernandez Lopez; M D Caballero; J F San Miguel
    Histiocytic cytophagic panniculitis: a rare late complication of allogeneic bone marrow transplantation.
    Bone marrow transplantation 1994;14(4):637-9.
  • 1994: J Almeida; M C del Cañizo; J Galende; B Vidriales; M J Nieto; M D Hernández; M J Rodríguez; J F San Miguel
    [Clonogenic cells of acute leukemia secondary to myeloproliferative and myelodysplastic syndromes].
    Sangre 1994;39(5):331-5.
  • 1994: A Macedo; A Orfao; J Ciudad; J F San Miguel
    [Phenotypic characterization of normal myeloid differentiation].
    Sangre 1994;39(4):277-82.
  • 1994: M C del Cañizo; J Almeida; J F San Miguel; A Orfao; M Gonzalez; A Lopez Borrasca
    The phenotype of L-CFU and its correlation with the immunological characteristics of the blast cell population in AML.
    Annals of hematology 1994;68(5):233-6.
  • 1994: R García-Sanz; I Alberca; L Vázquez; J M Hernández; A Castellanos; J F San Miguel
    [Control of oral anticoagulant treatment using an automated method].
    Sangre 1994;39(2):95-8.
  • 1994: A Orfao; J Ciudad; M C Lopez-Berges; A Lopez; B Vidriales; M D Caballero; B Valverde; M Gonzalez; J F San Miguel
    Acute lymphoblastic leukemia (ALL): detection of minimal residual disease (MRD) at flow cytometry.
    Leukemia & lymphoma 1994;13 Suppl 1():87-90.
  • 1993: R García; J M Hernández; M D Caballero; M González; J Galende; M C del Cañizo; L Vázquez; J F San Miguel
    Serum lactate dehydrogenase level as a prognostic factor in Hodgkin's disease.
    British journal of cancer 1993;68(6):1227-31.
  • 1993: M B Vidriales; A Orfao; M C López-Berges; M González; J M Hernandez; J Ciudad; A López; M J Moro; M Martínez; J F San Miguel
    Lymphoid subsets in acute myeloid leukemias: increased number of cells with NK phenotype and normal T-cell distribution.
    Annals of hematology 1993;67(5):217-22.
  • 1993: J M Hernández; I Sánchez; M González; A Orfao; R González-Sarmiento; J F San Miguel
    Acute lymphoid leukemias following either a previous chronic myelogenous leukemia or myelodysplastic syndrome: phenotypic and genomic differences.
    American journal of hematology 1993;43(4):256-8.
  • 1993: J Bladé; J F San Miguel; A Alcalá; J Maldonado; M A Sanz; J García-Conde; M J Moro; C Alonso; J Besalduch; A Zubizarreta
    Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(6):1165-71.
  • 1993: J F San Miguel; J M Hernandez; R Gonzalez; M Gonzalez; I Sanchez; A Orfao; M C del Cañizo; A Lopez-Borrasca
    Multiparameter analysis of blast cells in patients with acute leukemia following a primary myelodysplastic syndrome.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1993;131():393-400.
  • 1993: A Orfao; B Vidriales; M Gonzalez; M C Lopez-Berges; M C del Cañizo; J F San Miguel
    Diagnostic and prognostic importance of immunophenotyping in adults with acute myeloid leukemia.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1993;131():369-79.
  • 1992: G J Ruiz-Argüelles; E Lobato-Mendizábal; J F San-Miguel; M González; M D Caballero; A Ruiz-Argüelles; A Orfao; D Gómez-Almaguer; B Vidriales; G Ruiz-Reyes
    Long-term treatment results for acute megakaryoblastic leukaemia patients: a multicentre study.
    British journal of haematology 1992;82(4):671-5.
  • 1992: M D Caballero; M González; M C Cañizo; A Orfao; M J Nieto; J F San Miguel
    Concomitant chronic lymphocytic leukemia (CLL) and acute myeloid leukemia. Complete remission of CLL achieved with high-dose cytosine arabinoside.
    Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1992;6(8):856-8.
  • 1992: J M Hernández; J F San Miguel; M González; A Orfao; M C Cañizo; C Bascones; J Hernández; A López Borrasca
    Development of acute leukaemia after idiopathic myelofibrosis.
    Journal of clinical pathology 1992;45(5):427-30.
  • 1992: J F San Miguel; M González; A Gascón; M J Moro; J M Hernández; F Ortega; R Jiménez; L Guerras; M Romero; F Casanova
    Lymphoid subsets and prognostic factors in multiple myeloma. Cooperative Group for the Study of Monoclonal Gammopathies.
    British journal of haematology 1992;80(3):305-9.
  • 1992: M Gonzalez; J F San Miguel; A Gascon; M J Moro; J M Hernandez; F Ortega; R Jimenez; L Guerras; M Romero; F Casanova
    Increased expression of natural-killer-associated and activation antigens in multiple myeloma.
    American journal of hematology 1992;39(2):84-9.
  • 1992: A Orfao; J Ciudad; M González; J F San Miguel; A R García; M C López-Berges; F Ramos; M C Del Cañizo; A Ríos; M Sanz
    Prognostic value of S-phase white blood cell count in B-cell chronic lymphocytic leukemia.
    Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1992;6(1):47-51.
  • 1991: J M Hernández; R González-Sarmiento; C Martin; M González; I Sánchez; J Corral; A Orfao; M C Cañizo; J F San Miguel; A López-Borrasca
    Immunophenotypic, genomic and clinical characteristics of blast crisis of chronic myelogenous leukaemia.
    British journal of haematology 1991;79(3):408-14.
  • 1991: J M Hernández; J F San Miguel; M González; J M Moraleda; M J Moro; J Hernández; B Cuesta; A López Borrasca
    [Clinico-hematological characteristics of acute transformation of chronic myeloproliferative syndromes].
    Medicina clínica 1991;97(10):369-72.
  • 1991: E Gómez; J F San Miguel; M González; A Orfao; C López-Berges; A Ríos; A López Borrasca
    Heterogeneity of T cell lymphoblastic leukaemias.
    Journal of clinical pathology 1991;44(8):628-31.
  • 1991: J F San Miguel; J M Hernández; R González-Sarmiento; M González; I Sánchez; A Orfao; M C Cañizo; A López Borrasca
    Acute leukemia after a primary myelodysplastic syndrome: immunophenotypic, genotypic, and clinical characteristics.
    Blood 1991;78(3):768-74.
  • 1991: E Gómez; J F San Miguel; M González; A Orfao; M C Cañizo; J Ciudad; A López Borrasca
    [Phenotypic changes in refractory and relapse acute lymphoblastic leukemias].
    Sangre 1991;36(3):201-4.
  • 1991: J F San Miguel; M González; A Gascón; M J Moro; J M Hernández; F Ortega; R Jimenez; L Guerras; M Romero; F Casanova
    Immunophenotypic heterogeneity of multiple myeloma: influence on the biology and clinical course of the disease. Castellano-Leones (Spain) Cooperative Group for the Study of Monoclonal Gammopathies.
    British journal of haematology 1991;77(2):185-90.
  • 1991: J F San Miguel; M Moro; J Bladé; L Guerras; J Hernandez; R Jiminez-Galindo; F Ortega; M Gonzalez
    Interferon and dexamethasone in multiple myeloma patients refractory to chemotherapy.
    European journal of cancer (Oxford, England : 1990) 1991;27 Suppl 4():S48-9.
  • 1990: J F San Miguel; M Moro; J Bladé; L Guerras; J Hernandez; R Jimenez-Galindo; F Ortega; M Gonzalez
    Combination of interferon and dexamethasone in refractory multiple myeloma.
    Hematological oncology 1990;8(4):185-9.
  • 1990: A Ríos; M C Cañizo; M A Sanz; T Vallespí; G Sanz; M Torrabadella; F Gomis; C Ruiz; J F San Miguel
    Bone marrow biopsy in myelodysplastic syndromes: morphological characteristics and contribution to the study of prognostic factors.
    British journal of haematology 1990;75(1):26-33.
  • 1990: M C del Cañizo; J Almeida; J F San Miguel
    [The clonogenic cell in acute myeloblastic leukemia].
    Sangre 1990;35(2):125-7.
  • 1990: A Orfao; M Gonzalez; J F San Miguel; J F Tomas; M C Canizo; M C Lopez-Berges; J M Moraleda; A Lopez Borrasca
    Surface phenotype and immunoglobulin levels in B-cell chronic lymphocytic leukaemia.
    Haematologia 1990;23(1):49-56.
  • 1989: J Almeida; C Cañizo; I J Sánchez; M J Nieto; J F San Miguel; M González; A Orfao
    [Study of leukemic colony-forming units (CFU-L) in non-lymphoblastic malignant hemopathies].
    Sangre 1989;34(6):467-70.
  • 1989: G F Sanz; M A Sanz; T Vallespí; M C Cañizo; M Torrabadella; S García; D Irriguible; J F San Miguel
    Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients.
    Blood 1989;74(1):395-408.
  • 1989: M C del Cañizo; G Sanz; J F San Miguel; T Vallespi; D Irriguible; M Torrabadella; M A Sanz
    Chronic myelomonocytic leukemia--clinicobiological characteristics: a multivariate analysis in a series of 70 cases.
    European journal of haematology 1989;42(5):466-73.
  • 1989: J F San Miguel; E Ojeda; M Gonzalez; A Orfao; M C Cañizo; J Sanchez; A Lopez-Borrasca
    Prognostic value of immunological markers in acute myeloblastic leukemia.
    Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1989;3(2):108-11.
  • 1989: G F Sanz; M A Sanz; T Vallespí; M C Cañizo; S García; M Torrabadella; J F San Miguel; D Irriguible
    [Prediction of survival in myelodysplastic syndrome. Analysis of 2 scoring systems with prognostic value].
    Sangre 1989;34(1):41-6.
  • 1988: J F San Miguel; J F Tomás; M J Martín; A Ríos; J M Moraleda; M C Cañizo; M González; M J Nieto; J Sánchez; A López Borrasca
    [Non-Hodgkin's lymphomas. II. Prognostic factors].
    Sangre 1988;33(5):367-71.
  • 1988: J F Tomás; J F San Miguel; M J Martín; R Martínez; J M Moraleda; M González; M C Cañizo; E Ojeda; F Ramos; T Flores
    [Non-Hodgkin's lymphomas. I. Clinico-biological features in a series of 98 patients].
    Sangre 1988;33(5):361-6.
  • 1988: A Orfao; M González; J F San Miguel; M Corral; M J Nieto; M C Cañizo; J Hernández; J Fernández Calvo; A López Borrasca
    [Chronic B-cell lymphatic leukemia: autoimmune hemolytic anemias versus anemias caused by marrow failure].
    Sangre 1988;33(4):296-300.
  • 1988: E Ojeda; J F San Miguel; M González; C Cañizo; A Orfao; A Ríos; A López-Borrasca
    [Comparative study of the FAB classification and an immunologic classification model for the acute myeloid leukemias].
    Sangre 1988;33(4):291-5.
  • 1988: J F San Miguel; M Gonzalez; M C Cañizo; E Ojeda; A Orfao; M D Caballero; M J Moro; P Fisac; A Lopez Borrasca
    Leukemias with megakaryoblastic involvement: clinical, hematologic, and immunologic characteristics.
    Blood 1988;72(2):402-7.
  • 1988: M C Del Cañizo; E Ojeda; J F San Miguel; A Brufau; M González; A Orfao; A Ríos; A López Borrasca
    [Effect of a leukocyte medium conditioned with PHA on the proliferation and differentiation of leukemic cells].
    Sangre 1988;33(1):15-9.
  • 1988: A Orfao; M Gonzalez; J F San Miguel; M C Cañizo; P Galindo; M D Caballero; R Jimenez; A Lopez Borrasca
    Clinical and immunological findings in large B-cell chronic lymphocytic leukemia.
    Clinical immunology and immunopathology 1988;46(2):177-85.
  • 1987: M C del Canizo; J F San Miguel; M Gonzalez; J P Anta; A Orfao; A Lopez-Borrasca
    Discrepancies between morphologic, cytochemical, and immunologic characteristics in acute myeloblastic leukemia.
    American journal of clinical pathology 1987;88(1):38-42.
  • 1987: M Gonzalez; J F San Miguel; J P Anta; E Ojeda; A Lopez-Borrasca
    Cell lineage switches in blast crisis of a Ph1 positive chronic granulocytic leukemia.
    Haematologica 1987;72(3):249-51.
  • 1987: M C del Cañizo; J F San Miguel; A Gascón; A Rios; J M Moraleda; M González; J P Anta; J Sánchez; A López Borrasca
    [Myelodysplastic syndromes: characterization of a series of 56 patients classified according to FAB criteria].
    Sangre 1987;32(4):436-44.
  • 1987: A Orfao; M Gonzalez; J F San Miguel; M J Moro; J Fernandez-Calvo; M Carnero; P Galindo; A Lopez Borrasca
    Surface phenotype and clinical stages in B-cell chronic lymphocytic leukaemia.
    Haematologica 1987;72(1):39-43.
  • 1986: J F San Miguel; M Gonzalez; M C Cañizo; J P Anta; H Zola; A Lopez Borrasca
    Surface marker analysis in acute myeloid leukaemia and correlation with FAB classification.
    British journal of haematology 1986;64(3):547-60.
  • 1986: J M Moraleda; R Gonzalez; A Alegre; J P Anta; J F San Miguel
    Bone marrow necrosis and treatment with interferon.
    Journal of clinical pathology 1986;39(9):1045.
  • 1986: J F San Miguel; M González; M C Cañizo; J P Anta; J A Portero; A López-Borrasca
    TdT activity in acute myeloid leukemias defined by monoclonal antibodies.
    American journal of hematology 1986;23(1):9-17.
  • 1986: J F San Miguel; M González; M C Cañizo; J P Anta; J Hernández; F Ortega; L Borrasca
    The nature of blast cells in myelodysplastic syndromes evolving to acute leukaemia.
    Blut 1986;52(6):357-63.
  • 1986: A Orfao; M González; J F San Miguel; P Galindo; M J Moro; R Jiménez Galindo; C Bascones; A López Borrasca
    [Clinico-pathological features and clinical stages in chronic lymphatic leukemia. Multivariate analysis].
    Sangre 1986;31(5):550-8.
  • 1985: J F San Miguel; M González; M C Cañizo; J P Anta; J M Moraleda; A Ríos; M D Caballero; F Ortega; A López Borrasca
    [The megakaryoblastic component of mixed blast crises].
    Sangre 1985;30(3):330-6.
  • 1984: J F San Miguel; M González; M D Caballero; A Ríos; T Santoro; H Zola; A López Borrasca
    [Immunologic characterization of hairy-cell leukemia or tricholeukemia].
    Sangre 1984;29(3):280-6.
  • 1983: M C del Cañizo; J F San Miguel; M D Caballero; M González; A Ríos
    [Cytochemistry of tricholeukemia].
    Sangre 1983;28(6):794-5.
  • 1983: J F San Miguel; J A Portero; M Gonzaĺez; J P Plaza; M D Caballero; A De Cecilia; J J Fernández; A López Borrasca
    [The importance of terminal deoxyribonucleotidyl transferase in myeloblastic leukemias. Apropos of 2 cases].
    Sangre 1983;28(6):746-52.
Register to see more
Copyright © 2011 Elsevier Inc. All rights reserved.